Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

Adriana Carino^{1#}, Luigina Graziosi^{2#}, Silvia Marchianò¹, Michele Biagioli¹, Elisabetta Marino²,
Valentina Sepe³, Angela Zampella³, Eleonora Distrutti², Annibale Donini¹, Stefano Fiorucci¹

#Contributed equally to this work

¹ University of Perugia, Department of Medicine and Surgery, Perugia, Italy

² Azienda Ospedaliera di Perugia, Perugia, Italy

³ University of Naples Federico II, Department of Pharmacy, Naples, Italy

Acknowledgment

This work was supported by a grant from Regione Campania-POR Campania FESR 2014/2020 ***“Combattere la resistenza tumorale: piattaforma integrata multidisciplinare per un approccio tecnologico innovativo alle oncoterapie-Campania Oncoterapie” (Project N. B61G18000470007)***

Simple summary

Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-associated mortality worldwide. Although several new pharmacological approaches are currently developed, surgery remains the unique valid option of treatment but survival remains very poor over the last decades. Therefore, understanding the underlying molecular mechanisms of the gastric carcinogenesis and identifying sensitive biomarkers could be helpful for the prevention and treatment of the disease. Currently, the high-throughput sequencing techniques, in particular the transcriptomic analysis (RNA-seq) represents a validated technique to obtain a molecular characterization of human cancers. Moreover, it has been established that genetic susceptibility and environmental factors, such as microbial infections may contribute to carcinogenesis. We have characterized the different patterns of gene expression, using RNA-seq analysis and correlated these findings with gastric cancer histological subtypes.

Abstract

Gastric cancer is the fifth most common malignancy but the third leading cause of cancer-associated mortality worldwide. Therapy for gastric cancer remain largely suboptimal making the identification of novel therapeutic targets an urgent medical need. In the present study we have carried out a high-throughput sequencing of transcriptome expression in patients with gastric cancers. Twenty-four patients, among a series of 53, who underwent an attempt of curative surgery for gastric cancers in a single center, were enrolled. Patients were sub-grouped according to their histopathology into diffuse and intestinal types, and the transcriptome of the two subgroups assessed by RNAseq analysis and compared to the normal gastric mucosa. The results of this investigation demonstrated that the two histopathology phenotypes express two different patterns of gene expression. A total of 2064 transcripts were differentially expressed between neoplastic and non neoplastic tissues: 772 were specific for the intestinal type and 407 for the diffuse type. Only 885 transcripts were simultaneously differentially expressed by both tumors. The per pathway analysis demonstrated an enrichment of extracellular matrix and immune dysfunction in the intestinal type including CXCR2, CXCR1, FPR2, CARD14, EFNA2, AQP9, TRIP13, KLK11 and GHRL. At the univariate analysis reduced levels AQP9 was found to be a negative predictor of 4 years survival. In the diffuse type low levels CXCR2 and high levels of CARD14 mRNA were negative predictors of 4 years survival. In summary, we have identified a group of genes differentially regulated in the intestinal and diffuse histo-types of gastric cancers with AQP9, CARD14 and CXCR2 impacting on patients prognosis, although CXCR2 is the only factor independently impacting overall survival.

Keywords: gastric cancer, adenocarcinoma, biomarkers, tumor microenvironment, transcriptome expression.

Introduction

Gastric cancer is a highly prevalent cancer representing the fifth most frequent cancer worldwide [1-3]. While gastric cancer incidence has shown a trend of reduction over the last decades, gastric cancer-related mortality remains the third cause of cancer-related deaths worldwide. In Western countries, due to a lack of validated cancer screening programs, the large majority patients with gastric cancer are diagnosed in the advanced stages, greatly limiting the therapeutic options. Surgery remains the only potentially curative treatment, although current evidence supports adoption of perioperative therapies to improve a patient's survival [2]. Peritoneal metastases are the most frequent metastases detected in patients with advanced gastric cancers and the peritoneal cavity is a common site for gastric cancer recurrence following surgery [4] [5]. Overall, the presence of peritoneal carcinosis is associated to reduced survival rates and overwhelming symptoms [6] [7].

Two histopathology subtypes of gastric adenocarcinomas, intestinal (well-differentiated) and diffuse (undifferentiated), with a distinct morphologic appearance, pathogenesis, and genetic profiles have been identified [8-10]. The diffuse gastric cancer type is clinically more aggressive and associates with a higher rate of peritoneal involvement compared to the intestinal type [11,12]. However, the current histopathologic system fails to reflect the molecular and genetic heterogeneity of gastric cancers, and it is of clinical relevance to molecularly investigate gastric cancers in the attempt to identify novel targets for the prevention and treatment [9].

Several studies have shown a robust molecular heterogeneity of gastric adeno-carcinomas leading to different molecular classifications [11,13,14]. A widely used molecular classification proposed by the Genome Atlas Research Network Group (TCGA) has identified four major tumor molecular subtypes: Epstein-Barr virus positive, microsatellite unstable tumors, genomically stable tumors and tumors with chromosomal instability [14]. Although these subtypes have shown poor correlation with the prognosis, they have proven partially helpful in the selection of chemotherapy approaches suggesting that molecular profiling rather than histology could be implemented as a guide for the choice of treatment modality. Currently, only few biomarkers are available to predict treatment effectiveness in gastric cancer's patients including the level of expression of human epidermal growth factor receptor 2 (HER2) for trastuzumab and the programmed death-ligand 1 (PD-L1) for pembrolizumab [15,16], the last one allowed as a second line therapy for metastatic disease.

The introduction of Next Generation Sequencing (NGS), such as the RNA-sequencing technology, allows the application of large-scale functional genomics to cancer research and its application in clinical settings might allow the identification of individual gene expression profiles to be used as a potential biomarkers in the treatment of gastric cancer [17,18]. Previous studies have investigated differentially expressed genes between gastric cancer tissues and healthy gastric mucosa [17,19,20]. Moreover, several studies have identified stage-specific gene expression profiles and histological specific-gene profiles [21,22]. In this study, we report an integrative analyses of transcriptome sequencing (RNA-seq) and clinical and pathological characterization of patients with gastric cancers. We performed the NGS analysis based on histological types. Our principal goal was to identify new transcripts to be used as gastric cancer biomarkers and to which attribute a prognostic survival value. This novel comparative analysis generated a large amount of information that could be exploited to identify underlying molecular mechanisms of carcinogenesis, detection of disease markers and the identification of novel therapeutic targets.

Materials and Methods

Patients and specimens

Surgical specimen of 53 patients curatively operated for gastric cancers, were collected and analyzed according to the Helsinki declaration. Permission to collect post-surgical samples was granted to Prof. Fiorucci by the ethical committee of Umbria (CEAS). Permit F00001, n. 2266/2014 granted on February 19, 2014. An informed written consent was obtained by each patient before surgery.

Clinical data of these patients were retrieved from a prospectively collected database of GC patients operated between October 2014 and August 2017 at the Department of Surgery, Santa Maria della Misericordia Hospital (Italy). None of the patients received chemotherapy or radiation before surgery. All patients were followed up regularly until death every 6 months for the first 2 years from surgery and every year thereafter.

The study population includes 24 patients that were selected according to preoperative factors such as sex, age, gender, preoperative serum albumin level, preoperative N/L ratio (neutrophils to lymphocytes ratio); surgery related factors such as surgery type, lymphadenectomy level dissection, number of lymph nodes retrieved; associated organ resections and tumor related factors such as Lauren's Hystotype, Tumor location, Pathological stage according to AJCC tnm 8th edition [23] and peritoneal carcinomatosis development.

Venous blood sample was taken either the day before surgery or few days immediately before and collected in ethylenediaminetetraacetic acid-containing tube. The normal range of white blood cell (WBC) count was from 4,000 to 10,800 cells/mm³ and 3.5-4. The normal range of albumin was from 3,5 g/dl to 5,2 g/dl. N/L was calculated as neutrophil count divided by lymphocyte count. The patients were dichotomized at the median value of NLR, whereas patients were dichotomized according to the lower physiologic albumin levels for both intestinal and diffuse groups (Table 1). Finally, patients were separated in to two subgroup according to the median value of gene expression to perform OS analysis.

Statistical analysis

Patients descriptive analysis was generated, and their differences were investigated using Student t-test for quantitative data; for qualitative data, we used either Fisher's exact test or chi-square test. To compare overall survival (OS) between groups, the cumulative survival proportions were calculated using the product limit method of Kaplan-Meier, and differences were evaluated using

the log-rank test. Only variables that achieved statistical significance in the univariate analysis were subsequently evaluated in the multivariate analysis using Cox's proportional hazard regression model. A p value of less than 0.05 was considered statistically significant. All statistical analyses were performed using the MedCalc Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium) and PRISM 7.2 Graph PAD.

AmpliSeq Transcriptome

High-quality RNA was extracted from tumor gastric mucosa and healthy mucosa using the PureLink™ RNA Mini Kit (Thermo Fisher Scientific), according to the manufacturer's instructions. RNA quality and quantity were assessed with the Qubit® RNA HS Assay Kit and a Qubit 3.0 fluorometer followed by agarose gel electrophoresis. Libraries were generated using the Ion AmpliSeq™ Transcriptome Human Gene Expression Core Panel and Chef-Ready Kit (Thermo Fisher Scientific), according the manufacturer's instructions. Briefly, 10 ng of RNA was reverse transcribed with SuperScript™ Vilo™ cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) before library preparation on the Ion Chef™ instrument (Thermo Fisher Scientific, Waltham, MA). The resulting cDNA was amplified to prepare barcoded libraries using the Ion Code™ PCR Plate, and the Ion AmpliSeq™ Transcriptome Mouse Gene Expression Core Panel (Thermo Fisher Scientific, Waltham, MA), Chef-Ready Kit, according to the manufacturer's instructions. Barcoded libraries were combined to a final concentration of 100 pM, and used to prepare Template-Positive Ion Sphere™ (Thermo Fisher Scientific, Waltham, MA) Particles to load on Ion 540™ Chips, using the Ion 540™ Kit-Chef (Thermo Fisher Scientific, Waltham, MA). Sequencing was performed on an Ion S5™ Sequencer with Torrent Suite™ Software v6 (Thermo Fisher Scientific). The analyses were performed with a range of fold ≤ -2 and $\geq +2$ and a p value < 0.05 , using Transcriptome Analysis Console Software (version 4.0.2), certified for AmpliSeq analysis (Thermo-Fisher). The transcriptomic data have been deposited as dataset on Mendeley data repository (10.17632/d3ykf83tyv.1).

Functional enrichment analysis

DAVID software was employed to identify significantly enriched Gene Ontology functions in biological processes (BP), molecular function, and cellular component (CC) categories for histotype-specific genes [24].

Results

Patients

This study includes 24 gastric cancer patients who underwent resection surgery in our department between October 2014 to August 2017. This cohort of patients was further subdivided into two groups according to Lauren classification, as such two group of gastric cancer patients were identified: "intestinal group" and "diffuse group" (Table 1). The two groups include 12 patients each and were highly homogeneous as indicated in table 1, in term of mean age, gender and cancer stage. All patients underwent either a total or subtotal gastrectomy plus D1, D2 or D3 lymphadenectomy with a median number of harvested lymph nodes of 38.5 for intestinal group and 37 for diffuse group. The distribution of cancer stages (TNM8) was as follows: stage II: 1 (8.3%), stage III: 8 (66.7%), stage IV: 3 (25%) for intestinal group; stage III: 6 (50%), stage IV: 6 (50%) for diffuse group (Table 1). For survival analysis two patients in each group were excluded due to early postoperative death.

Patients		Intestinal (n=12)	Diffuse (n=12)	P
Age*		72.2 ±5.6	71.7±12.5	N.S.
Gender:				
	• M	9 (75%)	6 (50%)	N.S.
	• F	3 (25%)	6 (50%)	
pT:				
	• 1	0	0	N.S.
	• 2	0	1 (8.3%)	
	• 3	6 (50%)	5 (41.7%)	
	• 4	6 (50%)	6 (50%)	
pN:				
	• No	1 (8.3%)	1 (8.3%)	N.S.
	• N1	1 (8.3%)	0	
	• N2	3 (25%)	4 (33.3%)	
	• N3	7 (58.4)	7 (58.4)	
Stage:				
	• I	0	0	N.S.
	• II	1 (8.3%)	0	
	• III	8 (66.7%)	6 (50%)	
	• IV	3(25%)	6 (50%)	
Lymphonodal Harvasted**:		38.5	37	N.S.
Lymphonodal Ratio**		0.2	0.3	N.S.
Tumor Location:				
	• U	2 (16.7%)	4 (33.3%)	N.S.
	• M	6 (50%)	5 (41.7%)	
	• L	4 (33.3%)	3 (25%)	
Lymphoadenectomy:				
	• D1	1 (8.3%)	2 (16.7%)	N.S.
	• D2	11 (91.7%)	9 (75%)	
	• D3	0	1 (8.3%)	
Multiorgan resection:		2 (16.7%)	3 (25%)	N.S.
Peritoneal Carcinomatosis development:		4 (33.3%)	8 (66.6%)	N.S.
N/L ratio**:		2.3	3.5	N.S.
Sieric Albumin***		3.5	3.5	N.S.

Table 1. Clinical and pathological characteristics of the study population (n=24).

Transcriptome Analysis: Identification of common markers that characterized both diffuse and intestinal gastric cancer from healthy mucosa.

We performed an AmpliSeq Transcriptome analysis (RNA-seq) of 24 gastric tumors (and their matched normal tissues), according to the Lauren classification, as described in Material and Method section. As shown in Figure 1, the PCoA analysis revealed that healthy samples showed a homogeneous distribution, whereas both diffuse and intestinal tumors showed dissimilarities compared to normal tissues, but their signals only partially overlap (Figure 1A). The Scatter Plots depicted in Figure 1B, identify transcripts differentially expressed between diffuse tumor and healthy mucosa, or intestinal tumor and healthy mucosa.

The Venn Diagram analysis of differentially expressed transcripts, confirmed that the signals of diffuse and intestinal gastric cancer only partially overlap. We have identified the subset AB (885 transcripts) containing genes differentially expressed both in diffuse and intestinal gastric cancer vs healthy mucosa (Figure 2). These transcripts resulted modulated in same direction in both gastric cancer histotypes, confirming the existence of common molecular mechanisms underlying the development of the two main histological types of gastric cancer.

We have also detected transcripts differentially modulated only in diffuse gastric cancer vs healthy mucosa (Subset A containing 407 genes), and transcripts differentially modulated only in intestinal cancer vs healthy mucosa (Subset B containing 772 genes). These findings suggest that each gastric cancer histotype is characterized by specific molecular patterns. Therefore, we have performed a *per* pathways analysis of these different gene subsets using TAC software, to better dissect the most modulated mechanisms in diffuse and intestinal gastric cancers. For each subset (AB, A and B) we found several pathways that can be grouped in three principal clusters: a) proliferation, differentiation and metabolism ; b) inflammation and c) signaling. As expected, we found that the two types of gastric cancer (Subset AB) showed similar features regarding the modulation of genes involved in cell cycle, mitosis, cell division, DNA replication, extracellular matrix, as well as in the regulation of inflammation (IL-18, Chemokines, Cytokines, IL6 signaling pathways), or in cancer development and progression (PI3K-Akt-mTOR, VEGFA-VEGFR2, MAPK, Ras, EGF/EGFR signaling pathways), which differentiate both histotypes from healthy mucosa (see Supplementary Tables 1, 2 and 3).

In particular, we found an upregulation of several cell cycle regulators (Supplementary Table 1) such as the cyclin-dependent kinase CDK1, that induces the growth of gastric cancer cells [25], the M-phase inducers CDC25A and CD2C5B, which increased expression represents an early event in

gastric carcinogenesis common to both diffuse and intestinal cancer [26], the Cyclin B1 and B2 (CCNB1, CCNB2), upregulated to promote gastric cancer cell proliferation and tumor growth [27,28], or the E2Fs family and the correlated MYBL2 proto-oncogene, associated with cancer progression and poor overall survival [29,30]. Importantly we found also a modulation of genes involved in Epithelial to Mesenchymal Transition including TMPRSS4, that is upregulated in gastric cancer and increased the invasiveness of gastric cancer cells activating NF-Kb/MMP9 signaling [31], and Claudins (CLDN1, CLDN3, CLDN4, CLDN7), overexpressed in gastric cancer and associated with gastric cancer cell proliferation, invasion and maintenance of mesenchymal state [32-34]. Furthermore, we found an overexpression of ITGA2, which regulates Metastases and EMT [35], LAMC2 and WNT5A genes, that mediate invasion of gastric cancer cells [36]. Finally, great of relevance, we found an upregulation of Matrix Metalloproteinase family (MMP1, MMP3, MMP10, MMP12), that are overexpressed in gastric cancer as a result of NF-Kb activation thus promoting migration and invasion, and are associated with poor prognosis [37-40]. Among most downregulated genes we found GPX3, PTGER3 and LIPF (-47.5 and -435.63 of fold change for Diffuse and Intestinal tumors respectively), that resulted hypermethylated in gastric cancer [41,42]. The analysis of immune cluster revealed a great modulation of chemokine and cytokine signaling pathways (Supplementary Table 2). In particular, we found an upregulation of CCL3, CCL15, both overexpressed in the stromal compartment of gastric cancer [43], CCL20, that activates the pErk1/2-pAkt signaling via CCR6 inducing EMT pathways [44], but also CXCLs family (CXCL1, CXCL2, CXCL5 and CXCL16), that are induced by Cox2/Pge2 or Wnt5a signaling [45,46], and correlate with tumor malignant progression, invasiveness, gastric cancer cell migration and metastasis via the activation of CXCR2/Stat3 pathway [47-50].

We also detected an upregulation of several cytokines including IL1 β , IL11 and IL8, that promote metastasis, anti-apoptotic effects and maintenance of stemless properties by activating PI3K, Jak/Stat3 and Nf-Kb signaling pathways respectively [51-53]. Interestingly, we detected a downregulation of AQP4, which, when overexpressed, reduce gastric cancer cells proliferation [54]. The analysis of signaling cluster (Supplementary Table 3), revealed the upregulation of ANGPT2, whose overexpression promotes angiogenesis in gastric cancer [55], and S100A2, which is associated with tumor progression [56], whereas the expression of several genes was downregulated, including: CAB39L, a tumor suppressor hypermethylated in gastric cancer cells and tissues [57], HIF3A and SFRP1, targeted by several specific miRNA overexpressed in gastric cancer

[58-60], and FABP₄, whose expression in Tissue-resident memory T cells (Trms) infiltrating the tumor is reduced by PDL1 activation [61].

Furthermore, among overexpressed genes in both gastric cancer types, we found CEACAM1 and CEACAM6, two recognized markers of angiogenesis, invasion and metastasis in gastric cancer [62,63]. Finally, we also detected a modulation of genes that have been identified as tumor suppressors in other cancer types, including OGN, a gene that is downregulated in the breast cancer and that functions as Pi3K/Akt/mTOR suppressor [64].

Transcriptome Analysis: Identification of markers specific for Diffuse Gastric cancer.

To better characterize the specific phenotype of Diffuse Gastric cancer, we have then investigated the subset A of Venn Diagram (Figure 3). The analysis of this subset of genes, highlighted a modulation of transcripts involved in lipid metabolism and transport, metabolic pathways and transcription (Table 2).

Proliferation, differentiation and metabolism	Upregulated genes	Downregulated genes
Mesodermal Commitment Pathway	KLF5, ASCC3, <u>HNF4A</u> , HPRT1, HMGA2	ATP8B2, PBX1, ARID5B
Plasma lipoprotein assembly, remodeling, and clearance	<u>APOC2</u> , <u>APOE</u> , <u>APOC1</u> , NCEH1	<u>VLDLR</u>
Adipogenesis	KLF5, TRIB3, LMNA	CNTFR
Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways)	<u>FASN</u>	TM7SF2, <u>CYP27A1</u>
DNA Replication	CDC7, POLA2, POLE2	
G1 to S cell cycle control	POLE2, CREB3L1, POLA2	
Genotoxicity pathway	HIST1H2BI, HIST1H2BM, HIST1H3D	
Trans-sulfuration pathway	GCLM, DNMT1	GGT6
Oxidative Stress	HMOX1, NOX4	MT1X
Fatty Acid Biosynthesis	<u>FASN</u>	ECHDC2, ACACB
Apoptosis-related network due to altered Notch3	<u>APOE</u>	TRAF1, NGFRAP1
Ectoderm Differentiation	STC1	<u>CCL2</u> , CTNND2
G1 to S cell cycle control	POLE2, CREB3L1, POLA2	
Genotoxicity pathway	HIST1H2BI, HIST1H2BM, HIST1H3D	
Trans-sulfuration pathway	GCLM, DNMT1	GGT6
Oxidative Stress	HMOX1, NOX4	MT1X

Table 2. Principal pathways of Proliferation, differentiation and metabolism Cluster for the subset A.

In particular, we found an upregulation of several genes involved in proliferation and lipid metabolism such as HNF4A, functionally required for the development of gastric cancer regulating IDH1 [65], APOC1, recognized as new diagnostic and prognostic marker of gastric cancer [66], APOE, which is highly expressed in gastric cancers and correlates with progression and invasion [67,68], FASN, associated with diffuse gastric cancer and poor prognosis [69]. Conversely, we found a downregulation of VLDLR, whose genetic or epigenetic silencing contributes to gastric carcinogenesis [70], CYP27A1, which induces T cell dysfunction, thus promoting breast cancer progression [71] and CCL2, downregulated in diffuse gastric cancer primarily in advanced stages [72].

Although to a lesser extent, we also found a modulation of genes involved in inflammatory and signaling pathways (Supplementary Table 4 and 5). Interestingly, we found an upregulation of inflammatory genes including IL-18, marker of TAMs (Tumor associated macrophages) probably correlated with tumor invasion ability [73], IFN γ , that promotes gastric tumorigenesis in mice and regulates the expression of PD1 via JACK/Stat signaling [74,75], CCL22, that promotes EMT activating PI3K/Akt pathway and is correlated with peritoneal metastasis in gastric cancer patients [76,77], and CCL28, molecular target of Wnt/ β -catenin overexpressed in gastric cancer [78]. Furthermore, we found an overexpression of MMP-9, that promotes tumor invasion and is associated with poor prognosis in gastric cancer [79], ANXA1 and ANXA4, overexpressed in gastric cancer and associated with proliferation [80,81], AREG, that promotes malignant progression in several types of cancer [85]. Among the downregulated genes we found ADAMTS1, a metalloprotease with anti-angiogenic activity expressed at low levels in primary tumors [82]. Moreover, the 3 most overexpressed specific genes in diffuse gastric cancer resulted REG4, LCN2 and CEACAM5 (fold change of 16.97, 7.63 and 6.34 respectively): REG4 is generally overexpressed in gastric cancer and promotes peritoneal metastasis, increasing adhesion ability of gastric cancer cells [83]; LCN2 is overexpressed in gastric cancer mucosa infected with *H. pylori* and correlated with invasion, metastasis and poor prognosis of gastric cancer [84,85]; the expression of CEACAM5 is associated with tumor progression, invasion and migration and it is considered an independent prognostic predictor in patients with advanced stages of gastric cancer [86,87]. Conversely the most downregulated gene in diffuse gastric cancer subset is REG1A (fold change of -7.47), a tumor suppressor that, when overexpressed, reduces invasion and promotes apoptosis of gastric cancer cells, and that is typically downregulated in gastric cancer patients [88,89].

Transcriptome Analysis: Identification of markers specific for Intestinal Gastric cancer.

The analysis of intestinal gastric cancer subset indicated as subset B (Figure 4), immediately showed a stronger inflammatory component, likely due to its greater association with *H. pylori* infection. As shown in Table 3, the *per pathway* analysis of inflammatory cluster indicates a great modulation of genes involved in chemotaxis, inflammation, Innate and adaptative immunity (Table 3). First, we found a strong modulation of IL-18 signaling pathway with an overexpression of several genes including CCL4, whose increased expression in stromal compartment is associated with Intestinal gastric cancer [43], FN1, considered a prognostic biomarker in gastric cancer associated with a poor prognosis [90], and PTGS2, encoding for COX2 gene with a key role in the generation of the inflammatory microenvironment in tumor tissues inducing the expression of several cytokines and chemokines, which play tumor-promoting role [45,91]. In this pathway, we have also found a downregulation of CCL19, a tumor suppressor that reduces proliferation, migration and invasion in gastric cancer [92], and NROB2, whose downregulation in renal carcinoma is associated with development and progression of cancer [93]. Moreover the, Intestinal gastric cancer group is characterized by a modulation of chemokine signaling pathway, in which we found an increased expression of CXCR2, the IL8 receptor, associated with poor prognosis and metastasis [94], and conversely a downregulation of CCL19, that suppresses proliferation, migration and invasion of gastric cancer cells [92], and CXCL14, whose promoter hypermethylation is associated with depth of penetration and prognosis of gastric cancer [95].

Among inflammatory pathways, we found also an overexpression of several genes identified as diagnostic or prognostic markers of gastric cancer including E2F1, that induces upregulation of lncRNA HCG18 thus stimulating proliferation and migration of gastric cancer [96], TIMP1, a key gene in the development of gastric cancer recognized as a potential prognostic marker when co-expressed with MMP-7 [97,98], S100A9, a diagnostic and prognostic biomarker in gastric cancer [99,100], and SERPINE1, highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma [90]. Interestingly, also LAMA5 that promotes colorectal liver metastasis growth, resulted upregulated in intestinal gastric cancer [101].

Inflammation	Upregulated genes	Downregulated genes
IL-18 signaling pathway	NCF2, <u>CCL4</u> , PLOD3, BID, HCAR2, <u>FN1</u> , <u>PTGS2</u> , TGM2, ULBP2	FOXN3, KLF2, PRKCB, <u>CCL19</u> , DES, ACTA2, <u>NR0B2</u> , SPON1
Chemokine signaling pathway	<u>CXCR2</u> , <u>CCL4</u>	<u>CCL19</u> , <u>CCL11</u> , <u>CXCL14</u> , VAV3, PRKCB, PRKACB, AKT3
Spinal Cord Injury	E2F1, RTN4R, LILRB3, <u>PTGS2</u> , GJA1	SLIT2, SLIT3, RGMA, VIM
Prostaglandin Synthesis and Regulation	<u>PTGS2</u>	PTGFR, PTGER1, HPGD, HPGDS, AKR1C3, AKR1C1, AKR1C2
B Cell Receptor Signaling Pathway		CD79B, CD79A, BLNK, BLK, CR2
T-Cell antigen Receptor (TCR) Signaling Pathway	RIPK2	GRAP2, VAV3, VIM
IL1 and megakaryocytes in obesity	<u>TIMP1</u> , <u>S100A9</u>	SELENBP1, FCER1A
TGF-beta Receptor Signaling	BAMBI, <u>SERPINE1</u>	BMP4
Interferon type I signaling pathways	SOCS3	PDCD4, PTPRC
Inflammatory Response Pathway	<u>FN1</u> , <u>LAMA5</u>	CD40LG

Table 3. Principal pathways of Inflammation Cluster for the subset B.

The *per pathway* analysis of Signaling cluster in intestinal gastric cancer revealed a higher modulation of several signaling pathways such as PI3K-Akt-mTOR, MAPK, Ras, Jak/Stat, NFkB, VEGF (Table 4).

The pathway most modulated resulted the Focal Adhesion-PI3K-Akt-mTOR-signaling pathway with 14 upregulated genes and 4 downregulated genes. In particular we found an overexpression of OSMR, the receptor of Oncostatin M which promotes gastric cancer growth and metastasis [102], ITGA3, which promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer [103], EFNA2, one of the members of the ephrin family that are target of WNT/beta-catenin signaling implicated in the development of carcinogenesis [104], PDGFB, whose overexpression increases the growth, invasion, and angiogenesis of gastric carcinoma cells [105], FGFR4, that regulates proliferation and anti-apoptosis during gastric cancer progression [106], and SLC2A1, that induces tumor cell proliferation and metastasis in gastric Cancer when overexpressed [107].

Interestingly, among the other pathways we found an increased expression of OLR1, that facilitates metastasis of gastric cancer through driving EMT and PI3K/Akt/GSK3 β activation [108], and MMP7, identified as prognostic marker in gastric cancer when co-expressed with TIMP1 [98]. Conversely HMGCS2, identified as tumor suppressor with prognostic impact in prostate cancer, resulted downregulated also in intestinal gastric cancer subset [109].

Signaling	Upregulated genes	Downregulated genes
Focal Adhesion- PI3K-Akt-mTOR- signaling pathway	CSF3, COL4A2, FN1, <u>OSMR</u> , ITGA3, LAMA5, CSF3R, <u>EFNA2</u> , <u>PDGFB</u> , PGF, <u>FGFR4</u> , <u>SLC2A1</u> , PFKFB3, PFKFB4	PRLR, AKT3, FGF10, FGF7
Nuclear Receptors Meta-Pathway	CYP2B6, BHLHE40, <u>SLC2A1</u> , GPR115, <u>PTGS2</u> , ANGPTL4, <u>PDGFB</u> , FGFBP1, SLC6A8, SLC39A4, SLC39A5, SCD	NR0B2, <u>ALDH3A1</u> , SOD3, SNAIL2, ADH7, PLTP
PI3K-Akt Signaling Pathway	CSF3, COL4A2, FN1, <u>OSMR</u> , ITGA3, LAMA5, CSF3R, <u>EFNA2</u> , <u>PDGFB</u> , PGF, FGFR4	PRLR, AKT3, FGF10, FGF7, FLT3LG, COL9A2
MAPK Signaling Pathway	PDGFB, IL1R2, FGFR4, HSPA6, HSPA1B	AKT3, PRKACB, MRAS, CACNA2D3, <u>FGF7</u> , FGF10
VEGFA-VEGFR2 Signaling Pathway	NCF2, TNFRSF10C, GJA1, <u>PTGS2</u> , SELE, SOD2, PGF	PRKCB, PRKD1, TXNIP
GPCRs, Class A Rhodopsin-like	FPR1, CCRL2, ADORA2B	HTR2A, CCBP2, OR2W1, PTGER1, PTGFR
NRF2 pathway	<u>SLC2A1</u> , PDGFB, SLC6A8, SLC39A4, SLC39A5	SOD3, ADH7, ALDH3A1
Vitamin D Receptor Pathway	<u>TREM1</u> , CYP2B6, <u>S100A9</u> , S100A8, SALL4, CYP2D6	BGLAP, IGFBP5
Ras Signaling	<u>FGFR4</u>	PRKACB, MRAS, PAK3, AKT3, PLA2G1B, PRKCB
Regulatory circuits of the STAT3 signaling pathway	SOCS3, <u>OSMR</u> , CSF3R	PTPRC, PRKCB, DEPTOR
PPAR signaling pathway	SCD, ANGPTL4, FADS2, <u>QLR1</u>	<u>HMGCS2</u> , PLTP
Glucocorticoid Receptor Pathway	BHLHE40, FGFBP1, <u>PTGS2</u> , GPR115, <u>ANGPTL4</u>	SNAIL2
Gastrin Signaling Pathway	SERPINE1, <u>MMP7</u> , <u>PTGS2</u>	ARHGEF28, PRKD1
Wnt Signaling		PRKCB, ROR1, SERPINF1, SFRP2, SFRP5
Nuclear Receptors	NR5A2	THRB, ROR1, NR2F1, NR2F2
EGF/EGFR Signaling Pathway	GJA1, <u>E2F1</u>	VAV3, PRKCB
JAK/STAT	SOCS3, SIRPA, <u>TIMP1</u>	PRLR

Brain-Derived Neurotrophic Factor (BDNF) signaling pathway	SIRPA, NCF2	VAV3, KCNA3
ErbB Signaling Pathway		AKT3, PRKCB, PAK3
Insulin Signaling	<u>SLC2A1</u> , SOCS3	RPS6KA6
G Protein Signaling Pathways		PRKD1, PRKACB, AKAP12

Table 4. Principal pathways of Signaling Cluster for the subset B.

The analysis of Proliferation, differentiation and metabolism Cluster (Supplementary Table 6) revealed among others, the overexpression of several genes involved in invasion and metastasis of gastric cancer including CXCR1, that promotes malignant behavior of gastric cancer cells in vitro and in vivo inducing AKT and ERK1/2 phosphorylation [110,111], FPR2, that induces invasion and metastasis of gastric cancer cells and predicts the prognosis of patients acting as a novel prognostic marker [112], CARD14, involved in the progression from normal gastric epithelial to gastric cancer [113]. Finally, we found also a decreased expression of CLDN11, whose silencing is associated with increased invasiveness of gastric cancer cells [114]. Furthermore, the most upregulated genes specific for intestinal gastric cancer subset resulted OLFM4, involved in early gastric carcinogenesis and associated with prognostic significance in advanced stages [115], CDH17 and TFF3, specific markers of intestinal metaplasia gastric cancer patients [116], TRIM29, identified as oncogene in gastric cancer marker of lymph node metastasis [117,118], and SYT8, a promising target for the detection, prediction, and treatment of peritoneal metastasis of gastric cancer [119]. Conversely, among the transcripts more downregulated we found PSCA, whose reduced expression promotes gastric cancer proliferation and is related to poor prognosis [120], GKN2, which results downregulated in gastric cancer and when restored suppresses gastric tumorigenesis and cancer metastasis [121], and ALDH1A3, MLF1 and GREM1, all methylated at promoter level in gastric cancer [122].

Functional enrichment analysis of diffuse gastric-specific genes and intestinal-specific genes.

Finally, functional enrichment analysis was performed separately for gastric cancer histotype-specific genes, using DAVID tools [24] and the results were shown in Figure 5. For histotype-specific genes in diffuse gastric cancer tissues, functions including methylation, lipid metabolism (VLDL, Lipoprotein, Lipid Transport, Lipid metabolism, HDL), cell division and adhesion were significantly enriched (Figure 5). Conversely, the histotype-specific genes in intestinal gastric cancer samples were dramatically enriched in functions, including cell migration (cell membrane, extracellular matrix, metalloproteases, chemotaxis), vasculature development (angiogenesis, cell adhesion), apoptosis, but especially immune system regulation and inflammation (immunoglobulin domain, cytokine, innate immunity, cytokine-cytokine receptors interaction, adaptative immunity, prostaglandin metabolism, B cell activation) (Figure 5).

Accordingly, these data confirmed that as described above intestinal histotype-specific genes were significantly enriched in biological processes such chemotaxis, inflammation, Innate and adaptative immunity, cellular adhesion, angiogenesis and modulation of several signaling pathways, such as PI3K-Akt-mTOR, MAPK, Erk1/2, Ras, Jak/Stat, NFkB, VEGF, involved in their regulation.

Identification of histotype-specific genes.

In order to refine the analysis, the selection criteria were strengthened with a threshold of $FDR \leq 0.1$ and fold-change ≥ 3 applied. The stringent criteria generated a list of 7 upregulated and 0 downregulated transcripts in diffuse gastric cancer compared with healthy mucosa, whereas we found 14 upregulated transcripts and 11 downregulated transcripts in intestinal gastric cancer that met these criteria (Figure 6A and B).

Interestingly, we found 9 of these genes selected by using the stringent criteria, when we analyzed the Differential Expressed Genes (DEGs) between Intestinal gastric cancer and Diffuse gastric cancer samples (Figure 6C). In particular, genes encoding for N-formyl peptide receptor 2 (FPR2), Caspase recruitment domain-containing protein 1 (CARD14), C-X-C Motif Chemokine Receptor 2 (CXCR2), Ephrin A2 (EFNA2), C-X-C Motif Chemokine Receptor 1 (CXCR1), Aquaporin-9 (AQP9) and Thyroid Hormone Receptor Interactor 13 (TRIP13) resulted overexpressed in Intestinal Gastric cancer. Conversely, the expression of genes encoding for Ghrelin (GHRL) and Kallikrein Related Peptidase 11 (KLK11) was decreased in intestinal gastric cancer compared with diffuse histotype (Figure 6C). For these reasons, our results suggest that FPR2, CARD14, CXCR2, EFNA2, CXCR1, AQP9 TRIP13, along with GHRL and KLK11, could be used as promising biomarkers for gastric cancer diagnosis or prognostic evaluation.

Clinical results

The 4-year overall survival (4Y-OS) of the study population is 52 % (Figure 7A). The Kaplan-Meier survival curve showed that intestinal group presented a 4Y-oS of 80%. Conversely, diffuse group has revealed a worse prognosis with only 25% of patients alive after four years from surgery resection (Figure 7B). The difference was statistically significant.

According to the univariate analysis, performed as described in material and method section, the Intestinal group there was no clinical factor impacting the overall survival, whereas in the diffuse

group, male sex and High N/L ratio worsen patients' prognosis (Figure 8). In particular, in diffuse sub set females seems to have a better survival (4Y-OS: 40%) compared to males (4Y-OS: 0%) (Figure 8A). According to the median value of N/L ratio, patients were dichotomized into two subgroups. In the diffuse type, the survival was lower in the N/L higher group (40% vs 0%), as shown in figure 8C, in a statistically significant way. This was not confirmed in the intestinal subgroup (Figure 8D). In the diffuse group we eventually considered sex and N/L ratio status in multivariate analysis, but none of these factors turned out to be statistically independent.

At the end of our analysis we evaluated the impact of genes' expression in overall survival. For this purpose, patients were dichotomized into 2 groups according to the median value of expression each gene (Figure 9A). In the intestinal group only AQP9 gene expression showed an impact in patient survival: patients having a high AQP9 expression show a significant worse prognosis compared to patients with low expression (31.5% vs 100% 4Y-OS). In the diffuse group the expression of two genes, CARD14 and CXCR2, revealed an impact in patient survival. Despite the lower expression of these genes in diffuse group compared to intestinal group, the higher expression of CARD14 or CXCR2 was significantly associated with a worse prognosis in patients of diffuse subset (Figure 9C ad D). In particular, patients with a higher expression of CARD14 or CXCR2 show a 4Y-OS of 0% compared to patients having a lower expression of these genes, in which the 4Y-OS was of 42% and 40% respectively (Figure 9C and D). Furthermore, we considered both CARD14 and CXCR2 expression in multivariate analysis, and we found that in particular the CXCR2 expression resulted a statistically independent factor (Table 5)

Covariate	Regression Coef.	SE	Regression coef./SE	P	RR	95% CI RR
CARD 14	1,3882	0,9045	2,3556	0,128	4,0075	0,6869- 23,3795
CXCR2	2,5435	1,2094	4,4228	0,0355	12,7244	1,2033- 134,5504

Table 5. Multivariate analysis of gene expression for the diffuse sub set.

Discussion

In the present study we report an integrative approach combining the transcriptome sequencing (RNA-seq) and clinical-pathological phenotypes to a series of gastric cancer recorded in a single center in Italy [123]. In the clinical setting, the histopathological classifications by Lauren and the WHO, presently remain the two classifications most commonly used for the therapeutic decisional process [9]. According to the Lauren classification, gastric cancers are subdivided into two major histological subtypes, namely intestinal type and diffuse type adenocarcinoma. Both the intestinal and the diffuse types have been associated with chronic gastritis and *H. pylori* infection, that represents the main cause of gastric cancer, however, the histological changes leading to intestinal type are better characterized [124], suggesting that the later could be considered the end-result of an inflammatory multistep process that starts with *H. pylori* infection and progresses to chronic gastritis, atrophic gastritis and finally to intestinal metaplasia and dysplasia [7,124]. Conversely, the a development cascade for diffuse gastric cancer type, which convey a worst prognosis, is less defined. Despite the Lauren classification has been proposed more than half a century ago it maintains several advantages in term of easy handling and prognostic significance [125]. Therefore, a more detailed knowledge of the molecular subsets of two pathology entities described by Lauren may lead to a newer approach to gastric cancer tailored treatment [126].

In this study we provide the results of in deep characterization of the transcriptome patterns from 12 diffuse and 12 intestinal gastric cancer patients using high-throughput sequencing technology. We identified 885 transcripts differentially expressed in comparison to non-neoplastic tissue by both the diffuse and intestinal gastric cancer, that were considered to represent a group of recurrently deregulated genes potentially associated with tumorigenesis. As described in result section we found in this subset of transcripts a modulation of cell cycle regulators including, several genes involved in Epithelial to Mesenchymal Transition, chemokine and cytokine signaling pathways with an upregulation of genes such as CCL3, CCL15 [43], CCL20 [44], CXCLs family [45,46] [47-50], IL1b, IL11 and IL8 [51-53].

Surprisingly, the analysis of diffuse gastric cancer subset revealed in addition to a modulation of immune and proliferation pathways, also an upregulation of genes involved in proliferation and lipid metabolism such as HNF4A [65], APOC1, [66], APOE, [67,68], FASN [69], while the expression of VLDLR [70] and CCL2 [72], were downregulated.

The analysis of intestinal gastric cancer subset show a strong inflammatory component, likely due to its close association with *H. pylori* infection, with a robust modulation of genes involved in

chemotaxis, inflammation and innate and adaptive immunity. Moreover, the *per pathway* analysis revealed a higher modulation of several signaling pathways including PI3K-Akt-mTOR, MAPK, Ras, Jak/Stat, NFkB, VEGF.

These data were confirmed also by the functional enrichment analysis performed using DAVID tool. We found that the diffuse gastric cancer tissues were enriched for functions including methylation, lipid metabolism cell division and adhesion, whereas the intestinal gastric cancer group was dramatically enriched for genes involved in cell migration, vasculature development apoptosis, immune system regulation and inflammation.

The clinical analysis of our study population first confirmed that patients affected by diffuse type adenocarcinoma showed a worse prognosis with only 25% of patients survival after four years from surgical resection. None of the clinical factors investigated (Table 1) had any impact on intestinal group prognosis, while gender and preoperative inflammation status impacted on the survival of patients with diffuse gastric cancers, although at the multivariate analyses non of the clinical parameters maintained a statistical significance.

To better characterize the diffuse and intestinal gastric cancer transcriptome profile, we have strengthened the selection criteria for the analysis of differentially modulated genes (DEGs). Therefore, we have selected 9 genes differentially modulated between the intestinal and diffuse gastric cancer samples: FPR2, CARD14, CXCR2, EFNA2, CXCR1, AQP9, TRIP13, GHRL and KLK11, to be used as differentially expressed biomarkers for gastric cancers. In following this approach, we have first investigated whether the nine selected genes impact on overall patients survival. The results of this subset analysis demonstrated that in the intestinal group only the expression of AQP9 gene exerted a significant impact in patient survival. AQP9, a member of the aquaporin family, is involved in development of several tumors, promoting the proliferation, migration and invasion of tumor cells [127]. Previous studies have shown that AQP9 induces the growth and the migration of prostate cancer [128] and astrocytoma cells [129]. Conversely, AQP9 might inhibit the invasion of liver cancer cells and the proliferation of xenograft tumors [130], and also activates RAS signal and sensitize tumor cells to chemotherapy in colorectal cancer [131]. AQP9 had significant association with various immune infiltrating cells including CD8+ and CD4+ T cells, neutrophils, tumor associated macrophages (TAMs) and dendritic cells (DCs) [132,133]. However, high AQP9 expression was significantly correlated with worse prognosis in breast [134], colon and lung cancers [135], while predicted better prognosis in gastric cancer both in diffuse and intestinal gastric cancer [136]. Therefore, we can suppose that our results showing a worse prognosis for patients with high

levels of AQP9 in intestinal gastric cancer subset, may be due to the presence of a stronger immune and inflammatory component. Moreover, it was been shown that gene markers of M2 macrophages were moderately to very strongly correlated with AQP9 expression [137], suggesting that AQP9 might be involved in the polarization of TAMs and in the immunosuppression in cancer. In the diffuse gastric cancer group, both CARD14 and CXCR2 expression, revealed an impact in patient survival. In this subset, the higher expression of CARD14 or CXCR2 was significantly associated with a worse patient prognosis. Importantly, the multivariate analysis revealed that the CXCR2 expression resulted a statistically independent factor.

CARD14, is a member of the Caspase recruitment domain family of proteins, which play an important role in immune and inflammatory response, and cell survival and proliferation. It is strongly expressed in the epidermal keratinocyte of the skin and is involved in inflammatory disorders of the human skin, such as psoriasis [138,139]. CARD14 isoforms are expressed in several hematopoietic cells and tissues such as bronchus, cervix, colon and lung as well as cancer cell lines derived from these tissues [140,141]. In particular, it was shown that CARD14 resulted overexpressed in breast cancer cell lines, and its knockdown led to decreased breast cancer cell proliferation and migration ability, accompanied by the induction of cell death through NF- κ B [142].

CXCR2, is a potent pro-tumorigenic chemokine receptor that can induce inflammation in the tumor microenvironment by mediating the recruitment of different stromal cells and thus promoting the progression of cancer cells [143]. CXCR2-targeted therapy has shown previously promising results in several solid tumors, including breast cancer [144], pancreatic cancer [145], and rhabdomyosarcoma [146]. More recently, its expression has been associated with the prognosis of patients with gastric cancer [48]. CXCR2 ligands, produced by TAM, significantly promote proliferation and migration of gastric cancer cells through activating a CXCR2/STAT3 feed-forward loop [147]. Gastric cancer cells in turn, secrete TNF- α to induce the release of CXCR2 ligands from macrophages [48]. Furthermore, CXCR2 along with CXCR4 overexpression, was associated with more advanced tumor stages and poorer survival in gastric cancer patients [94]. CXCR4 and CXCR2 activate NF- κ B and STAT3 signaling, while NF- κ Bp65 can then transcriptionally activate CXCR4 and STAT3 can activate CXCR2 expression [94]. It was been shown that this crosstalk between CXCR4 and CXCR2 contributed to EMT, migration and invasion of gastric cancer. Conversely, the inhibition of CXCR2 pathway in gastric cancer cells suppressed migration and metastasis of gastric cancer both in vitro and in vivo [48]. Therefore, the interaction between CXCR2 and tumor microenvironment results of critical importance for tumor progression [148]. Recent studies have

been demonstrated that the blockade of the receptor with specific inhibitors [149], as well as the inhibition of the recruitment of immune cells via the CXCL1-CXCR2 axis [143], appear a promising therapy for gastric cancer primarily for diffuse subtype.

In summary our analysis detected 7 genes up regulated in the Intestinal type and 2 genes down regulated when compared to the healthy mucosa, with AQP9 expression influencing also patients prognosis. In the diffuse type, with an *ab-initio* worse prognosis, we were able to detect two genes, CARD14 and CXCR2, impacting prognosis. In particular CXCR2 seems to play a key role, resulting the only factor independently impacting overall survival.

The present study suggests that targeting AQP9 and CXCR2 may represent a novel strategy for gastric cancer therapy, in intestinal and diffuse patients respectively. However, further studies will be needed to confirm the role of these genes as therapeutic targets and biomarkers in gastric cancer.

References

1. Rawla, P.; Barsouk, A. Epidemiology of gastric cancer: global trends, risk factors and prevention. *Prz Gastroenterol* **2019**, *14*, 26-38, doi:10.5114/pg.2018.80001.
2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **2018**, *68*, 394-424, doi:10.3322/caac.21492.
3. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. *CA Cancer J Clin* **2015**, *65*, 87-108, doi:10.3322/caac.21262.
4. Marano, L.; Polom, K.; Patriti, A.; Roviello, G.; Falco, G.; Stracqualursi, A.; De Luca, R.; Petrioli, R.; Martinotti, M.; Generali, D., et al. Surgical management of advanced gastric cancer: An evolving issue. *Eur J Surg Oncol* **2016**, *42*, 18-27, doi:10.1016/j.ejso.2015.10.016.
5. Shiozaki, H.; Elimova, E.; Slack, R.S.; Chen, H.C.; Staerckel, G.A.; Sneige, N.; Shimodaira, Y.; Sagebiel, T.; Lee, J.H.; Bhutani, M.S., et al. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. *J Surg Oncol* **2016**, *113*, 29-35, doi:10.1002/jso.24087.
6. Gill, R.S.; Al-Adra, D.P.; Nagendran, J.; Campbell, S.; Shi, X.; Haase, E.; Schiller, D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. *J Surg Oncol* **2011**, *104*, 692-698, doi:10.1002/jso.22017.
7. Correa, P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* **1992**, *52*, 6735-6740.
8. LAUREN, P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. *Acta Pathol Microbiol Scand* **1965**, *64*, 31-49, doi:10.1111/apm.1965.64.1.31.
9. Berlth, F.; Bollschweiler, E.; Drebber, U.; Hoelscher, A.H.; Moenig, S. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. *World J Gastroenterol* **2014**, *20*, 5679-5684, doi:10.3748/wjg.v20.i19.5679.
10. Spoto, C.P.E.; Gullo, I.; Carneiro, F.; Montgomery, E.A.; Brosens, L.A.A. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. *Semin Diagn Pathol* **2018**, *35*, 170-183, doi:10.1053/j.semdp.2018.01.004.
11. Cristescu, R.; Lee, J.; Nebozhyn, M.; Kim, K.M.; Ting, J.C.; Wong, S.S.; Liu, J.; Yue, Y.G.; Wang, J.; Yu, K., et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nat Med* **2015**, *21*, 449-456, doi:10.1038/nm.3850.
12. Sohn, B.H.; Hwang, J.E.; Jang, H.J.; Lee, H.S.; Oh, S.C.; Shim, J.J.; Lee, K.W.; Kim, E.H.; Yim, S.Y.; Lee, S.H., et al. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. *Clin Cancer Res* **2017**, doi:10.1158/1078-0432.CCR-16-2211.
13. Lei, Z.; Tan, I.B.; Das, K.; Deng, N.; Zouridis, H.; Pattison, S.; Chua, C.; Feng, Z.; Guan, Y.K.; Ooi, C.H., et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. *Gastroenterology* **2013**, *145*, 554-565, doi:10.1053/j.gastro.2013.05.010.
14. Network, C.G.A.R. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* **2014**, *513*, 202-209, doi:10.1038/nature13480.
15. Van Cutsem, E.; Bang, Y.J.; Feng-Yi, F.; Xu, J.M.; Lee, K.W.; Jiao, S.C.; Chong, J.L.; López-Sánchez, R.I.; Price, T.; Gladkov, O., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer* **2015**, *18*, 476-484, doi:10.1007/s10120-014-0402-Y.
16. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. *Clin Cancer Res* **2019**, *25*, 3753-3758, doi:10.1158/1078-0432.CCR-18-4070.
17. Ng, H.K.; Roukos, D.H.; Iacopetta, B.; Ku, C.-S. Next-Generation Sequencing in Cancer Epigenomics and Potential Clinical Applications. In *Next Generation Sequencing in Cancer Research*, Springer, New York, NY: 2013; pp. 31-55.

18. de Klerk, E.; den Dunnen, J.T.; 't Hoen, P.A. RNA sequencing: from tag-based profiling to resolving complete transcript structure. *Cell Mol Life Sci* **2014**, *71*, 3537-3551, doi:10.1007/s00018-014-1637-9.
19. Luo, Y.H.; Liang, L.; He, R.Q.; Wen, D.Y.; Deng, G.F.; Yang, H.; He, Y.; Ma, W.; Cai, X.Y.; Chen, J.Q., et al. RNA-sequencing investigation identifies an effective risk score generated by three novel lncRNAs for the survival of papillary thyroid cancer patients. *Oncotarget* **2017**, *8*, 74139-74158, doi:10.18632/oncotarget.18274.
20. Han, H.; Jiang, X. Disease Biomarker Query from RNA-Seq Data. *Cancer Inform* **2014**, *13*, 81-94, doi:10.4137/CIN.S13876.
21. Wang, Y. Identifying key stage-specific genes and transcription factors for gastric cancer based on RNA-sequencing data. *Medicine (Baltimore)* **2017**, *96*, e5691, doi:10.1097/MD.0000000000005691.
22. Kim, Y.H.; Liang, H.; Liu, X.; Lee, J.S.; Cho, J.Y.; Cheong, J.H.; Kim, H.; Li, M.; Downey, T.J.; Dyer, M.D., et al. AMPK α modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. *Cancer Res* **2012**, *72*, 2512-2521, doi:10.1158/0008-5472.CAN-11-3870.
23. Amin, M.B.; Greene, F.L.; Edge, S.B.; Compton, C.C.; Gershenwald, J.E.; Brookland, R.K.; Meyer, L.; Gress, D.M.; Byrd, D.R.; Winchester, D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin* **2017**, *67*, 93-99, doi:10.3322/caac.21388.
24. Huang, d.W.; Sherman, B.T.; Lempicki, R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **2009**, *4*, 44-57, doi:10.1038/nprot.2008.211.
25. Gao, S.Y.; Li, J.; Qu, X.Y.; Zhu, N.; Ji, Y.B. Downregulation of Cdk1 and cyclinB1 expression contributes to oridonin-induced cell cycle arrest at G2/M phase and growth inhibition in SGC-7901 gastric cancer cells. *Asian Pac J Cancer Prev* **2014**, *15*, 6437-6441, doi:10.7314/apjcp.2014.15.15.6437.
26. Xing, X.; Chen, J.; Chen, M. Expression of CDC25 phosphatases in human gastric cancer. *Dig Dis Sci* **2008**, *53*, 949-953, doi:10.1007/s10620-007-9964-4.
27. Zhang, H.P.; Li, S.Y.; Wang, J.P.; Lin, J. Clinical significance and biological roles of cyclins in gastric cancer. *Onco Targets Ther* **2018**, *11*, 6673-6685, doi:10.2147/OTT.S171716.
28. Shi, Q.; Wang, W.; Jia, Z.; Chen, P.; Ma, K.; Zhou, C. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. *Oncotarget* **2016**, *7*, 36489-36500, doi:10.18632/oncotarget.9269.
29. Manicum, T.; Ni, F.; Ye, Y.; Fan, X.; Chen, B.C. Prognostic values of. *Biosci Rep* **2018**, *38*, doi:10.1042/BSR20181264.
30. Feng, Y.; Shi, C.; Wang, D.; Wang, X.; Chen, Z. Integrated Analysis of DNA Copy Number Changes and Gene Expression Identifies Key Genes in Gastric Cancer. *J Comput Biol* **2020**, *27*, 877-887, doi:10.1089/cmb.2019.0149.
31. Jin, J.; Shen, X.; Chen, L.; Bao, L.W.; Zhu, L.M. TMPRSS4 promotes invasiveness of human gastric cancer cells through activation of NF- κ B/MMP-9 signaling. *Biomed Pharmacother* **2016**, *77*, 30-36, doi:10.1016/j.biopha.2015.11.002.
32. Eftang, L.L.; Esbensen, Y.; Tannæs, T.M.; Blom, G.P.; Bukholm, I.R.; Bukholm, G. Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival. *BMC Cancer* **2013**, *13*, 586, doi:10.1186/1471-2407-13-586.
33. Jung, H.; Jun, K.H.; Jung, J.H.; Chin, H.M.; Park, W.B. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. *J Surg Res* **2011**, *167*, e185-191, doi:10.1016/j.jss.2010.02.010.
34. Wu, Z.; Shi, J.; Song, Y.; Zhao, J.; Sun, J.; Chen, X.; Gao, P.; Wang, Z. Claudin-7 (CLDN7) is overexpressed in gastric cancer and promotes gastric cancer cell proliferation, invasion and maintains mesenchymal state. *Neoplasia* **2018**, *65*, 349-359, doi:10.4149/neo_2018_170320N200.
35. Dong, J.; Wang, R.; Ren, G.; Li, X.; Wang, J.; Sun, Y.; Liang, J.; Nie, Y.; Wu, K.; Feng, B., et al. HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer. *Clin Cancer Res* **2017**, *23*, 3461-3473, doi:10.1158/1078-0432.CCR-16-2180.

36. Yamamoto, H.; Kitadai, Y.; Oue, N.; Ohdan, H.; Yasui, W.; Kikuchi, A. Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. *Gastroenterology* **2009**, *137*, 242-252, 252.e241-246, doi:10.1053/j.gastro.2009.02.003.
37. Zhou, Y.; Li, G.; Wu, J.; Zhang, Z.; Wu, Z.; Fan, P.; Hao, T.; Zhang, X.; Li, M.; Zhang, F., et al. Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. *Tumour Biol* **2010**, *31*, 549-558, doi:10.1007/s13277-010-0068-y.
38. Xu, J.; E, C.; Yao, Y.; Ren, S.; Wang, G.; Jin, H. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. *Oncol Lett* **2016**, *12*, 2403-2408, doi:10.3892/ol.2016.5013.
39. Kwon, C.H.; Moon, H.J.; Park, H.J.; Choi, J.H.; Park, D.Y. S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF- κ B activation in gastric cancer cells. *Mol Cells* **2013**, *35*, 226-234, doi:10.1007/s10059-013-2269-x.
40. Yu, C.; Chen, J.; Ma, J.; Zang, L.; Dong, F.; Sun, J.; Zheng, M. Identification of Key Genes and Signaling Pathways Associated with the Progression of Gastric Cancer. *Pathol Oncol Res* **2020**, *26*, 1903-1919, doi:10.1007/s12253-019-00781-3.
41. Zhang, X.; Yang, J.J.; Kim, Y.S.; Kim, K.Y.; Ahn, W.S.; Yang, S. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. *Int J Oncol* **2010**, *36*, 405-414.
42. Kim, H.J.; Kang, T.W.; Haam, K.; Kim, M.; Kim, S.K.; Kim, S.Y.; Lee, S.I.; Song, K.S.; Jeong, H.Y.; Kim, Y.S. Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis. *Exp Mol Med* **2018**, *50*, 1-14, doi:10.1038/s12276-018-0179-x.
43. Raja, U.M.; Gopal, G.; Shirley, S.; Ramakrishnan, A.S.; Rajkumar, T. Immunohistochemical expression and localization of cytokines/chemokines/growth factors in gastric cancer. *Cytokine* **2017**, *89*, 82-90, doi:10.1016/j.cyto.2016.08.032.
44. Han, G.; Wu, D.; Yang, Y.; Li, Z.; Zhang, J.; Li, C. CrkL mediates CCL20/CCR6-induced EMT in gastric cancer. *Cytokine* **2015**, *76*, 163-169, doi:10.1016/j.cyto.2015.05.009.
45. Echizen, K.; Hirose, O.; Maeda, Y.; Oshima, M. Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. *Cancer Sci* **2016**, *107*, 391-397, doi:10.1111/cas.12901.
46. Takiguchi, G.; Nishita, M.; Kurita, K.; Kakeji, Y.; Minami, Y. Wnt5a-Ror2 signaling in mesenchymal stem cells promotes proliferation of gastric cancer cells by activating CXCL16-CXCR6 axis. *Cancer Sci* **2016**, *107*, 290-297, doi:10.1111/cas.12871.
47. Yamamoto, Y.; Kuroda, K.; Sera, T.; Sugimoto, A.; Kushiya, S.; Nishimura, S.; Togano, S.; Okuno, T.; Yoshii, M.; Tamura, T., et al. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer. *Anticancer Res* **2019**, *39*, 6645-6652, doi:10.21873/anticancer.13879.
48. Zhou, Z.; Xia, G.; Xiang, Z.; Liu, M.; Wei, Z.; Yan, J.; Chen, W.; Zhu, J.; Awasthi, N.; Sun, X., et al. A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis. *Clin Cancer Res* **2019**, *25*, 3317-3328, doi:10.1158/1078-0432.CCR-18-3567.
49. Cheng, W.L.; Wang, C.S.; Huang, Y.H.; Tsai, M.M.; Liang, Y.; Lin, K.H. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. *Ann Oncol* **2011**, *22*, 2267-2276, doi:10.1093/annonc/mdq739.
50. Ikeda, T.; Nishita, M.; Hoshi, K.; Honda, T.; Kakeji, Y.; Minami, Y. Mesenchymal stem cell-derived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1. *Cancer Sci* **2020**, *111*, 1254-1265, doi:10.1111/cas.14339.
51. Yu, A.; Wang, Y.; Bian, Y.; Chen, L.; Guo, J.; Shen, W.; Chen, D.; Liu, S.; Sun, X. IL-1 β promotes the nuclear translocation of S100A4 protein in gastric cancer cells MGC803 and the cell's stem-like properties through PI3K pathway. *J Cell Biochem* **2018**, *119*, 8163-8173, doi:10.1002/jcb.26813.
52. Ma, J.; Song, X.; Xu, X.; Mou, Y. Cancer-Associated Fibroblasts Promote the Chemo-resistance in Gastric Cancer through Secreting IL-11 Targeting JAK/STAT3/Bcl2 Pathway. *Cancer Res Treat* **2019**, *51*, 194-210, doi:10.4143/crt.2018.031.

53. Zhai, J.; Shen, J.; Xie, G.; Wu, J.; He, M.; Gao, L.; Zhang, Y.; Yao, X.; Shen, L. Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. *Cancer Lett* **2019**, *454*, 37-43, doi:10.1016/j.canlet.2019.04.002.
54. Li, J.; Wang, L.; He, F.; Li, B.; Han, R. Long noncoding RNA LINC00629 restrains the progression of gastric cancer by upregulating AQP4 through competitively binding to miR-196b-5p. *J Cell Physiol* **2020**, *235*, 2973-2985, doi:10.1002/jcp.29203.
55. Chen, Z.; Zhu, S.; Hong, J.; Soutto, M.; Peng, D.; Belkhir, A.; Xu, Z.; El-Rifai, W. Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis. *Gut* **2016**, *65*, 925-934, doi:10.1136/gutjnl-2014-308416.
56. Chivu Economescu, M.; Necula, L.G.; Dragu, D.; Badea, L.; Dima, S.O.; Tudor, S.; Nastase, A.; Popescu, I.; Diaconu, C.C. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. *Hepatogastroenterology* **2010**, *57*, 1453-1464.
57. Li, W.; Wong, C.C.; Zhang, X.; Kang, W.; Nakatsu, G.; Zhao, Q.; Chen, H.; Go, M.Y.Y.; Chiu, P.W.Y.; Wang, X., et al. CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1 α axis to inhibit gastric tumorigenesis. *Oncogene* **2018**, *37*, 6383-6398, doi:10.1038/s41388-018-0402-1.
58. Xu, Z.; Lv, H.; Wang, Y.; Hu, C.; Chen, S.; Du, Y.; Shi, C.; Cheng, X. HAND2-AS1 Inhibits Gastric Adenocarcinoma Cells Proliferation and Aerobic Glycolysis via miRNAs Sponge. *Cancer Manag Res* **2020**, *12*, 3053-3068, doi:10.2147/CMAR.S222878.
59. Feng, C.; She, J.; Chen, X.; Zhang, Q.; Zhang, X.; Wang, Y.; Ye, J.; Shi, J.; Tao, J.; Feng, M., et al. Exosomal miR-196a-1 promotes gastric cancer cell invasion and metastasis by targeting SFRP1. *Nanomedicine (Lond)* **2019**, *14*, 2579-2593, doi:10.2217/nnm-2019-0053.
60. Cui, H.B.; Ge, H.E.; Wang, Y.S.; Bai, X.Y. MiR-208a enhances cell proliferation and invasion of gastric cancer by targeting SFRP1 and negatively regulating MEG3. *Int J Biochem Cell Biol* **2018**, *102*, 31-39, doi:10.1016/j.biocel.2018.06.004.
61. Lin, R.; Zhang, H.; Yuan, Y.; He, Q.; Zhou, J.; Li, S.; Sun, Y.; Li, D.Y.; Qiu, H.B.; Wang, W., et al. Fatty Acid Oxidation Controls CD8. *Cancer Immunol Res* **2020**, *8*, 479-492, doi:10.1158/2326-6066.CIR-19-0702.
62. Shi, J.F.; Xu, S.X.; He, P.; Xi, Z.H. Expression of carcinoembryonic antigen-related cell adhesion molecule 1(CEACAM1) and its correlation with angiogenesis in gastric cancer. *Pathol Res Pract* **2014**, *210*, 473-476, doi:10.1016/j.prp.2014.03.014.
63. Zhang, Y.; Zang, M.; Li, J.; Ji, J.; Zhang, J.; Liu, X.; Qu, Y.; Su, L.; Li, C.; Yu, Y., et al. CEACAM6 promotes tumor migration, invasion, and metastasis in gastric cancer. *Acta Biochim Biophys Sin (Shanghai)* **2014**, *46*, 283-290, doi:10.1093/abbs/gmu001.
64. Xu, T.; Zhang, R.; Dong, M.; Zhang, Z.; Li, H.; Zhan, C.; Li, X. Osteoglycin (OGN) Inhibits Cell Proliferation and Invasiveness in Breast Cancer via PI3K/Akt/mTOR Signaling Pathway. *Onco Targets Ther* **2019**, *12*, 10639-10650, doi:10.2147/OTT.S222967.
65. Xu, C.; Ooi, W.F.; Qamra, A.; Tan, J.; Chua, B.Y.; Ho, S.W.T.; Das, K.; Adam Isa, Z.F.; Li, Z.; Yao, X., et al. pathway mapping identifies wild-type. *Gut* **2020**, *69*, 231-242, doi:10.1136/gutjnl-2018-318025.
66. Yi, J.; Ren, L.; Wu, J.; Li, W.; Zheng, X.; Du, G.; Wang, J. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. *Ann Transl Med* **2019**, *7*, 380, doi:10.21037/atm.2019.07.59.
67. Shi, X.; Xu, J.; Wang, J.; Cui, M.; Gao, Y.; Niu, H.; Jin, H. Expression analysis of apolipoprotein E and its associated genes in gastric cancer. *Oncol Lett* **2015**, *10*, 1309-1314, doi:10.3892/ol.2015.3447.
68. Sakashita, K.; Tanaka, F.; Zhang, X.; Mimori, K.; Kamohara, Y.; Inoue, H.; Sawada, T.; Hirakawa, K.; Mori, M. Clinical significance of ApoE expression in human gastric cancer. *Oncol Rep* **2008**, *20*, 1313-1319.
69. Ezzeddini, R.; Taghikhani, M.; Somi, M.H.; Samadi, N.; Rasaei, M.J. Clinical importance of FASN in relation to HIF-1 α and SREBP-1c in gastric adenocarcinoma. *Life Sci* **2019**, *224*, 169-176, doi:10.1016/j.lfs.2019.03.056.
70. Takada, H.; Imoto, I.; Tsuda, H.; Nakanishi, Y.; Sakakura, C.; Mitsufuji, S.; Hirohashi, S.; Inazawa, J. Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. *Oncogene* **2006**, *25*, 6554-6562, doi:10.1038/sj.onc.1209657.
71. Ma, L.; Wang, L.; Nelson, A.T.; Han, C.; He, S.; Henn, M.A.; Menon, K.; Chen, J.J.; Baek, A.E.; Vardanyan, A., et al. 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell

- dysfunction, promoting breast cancer progression. *Cancer Lett* **2020**, 493, 266-283, doi:10.1016/j.canlet.2020.08.020.
72. Sánchez-Zauco, N.; Torres, J.; Gómez, A.; Camorlinga-Ponce, M.; Muñoz-Pérez, L.; Herrera-Goepfert, R.; Medrano-Guzmán, R.; Giono-Cerezo, S.; Maldonado-Bernal, C. Correction to: Circulating blood levels of IL-6, IFN- γ , and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. *BMC Cancer* **2017**, 17, 669, doi:10.1186/s12885-017-3657-y.
73. Shen, Z.; Seppänen, H.; Vainionpää, S.; Ye, Y.; Wang, S.; Mustonen, H.; Puolakkainen, P. IL10, IL11, IL18 are differently expressed in CD14+ TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. *Cytokine* **2012**, 59, 352-357, doi:10.1016/j.cyto.2012.04.033.
74. Zuo, X.; Deguchi, Y.; Xu, W.; Liu, Y.; Li, H.S.; Wei, D.; Tian, R.; Chen, W.; Xu, M.; Yang, Y., et al. PPAR δ and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. *Gastroenterology* **2019**, 157, 163-178, doi:10.1053/j.gastro.2019.03.018.
75. Ayers, M.; Lunceford, J.; Nebozhyn, M.; Murphy, E.; Loboda, A.; Kaufman, D.R.; Albright, A.; Cheng, J.D.; Kang, S.P.; Shankaran, V., et al. IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest* **2017**, 127, 2930-2940, doi:10.1172/JCI91190.
76. Wei, Y.; Wang, T.; Song, H.; Tian, L.; Lyu, G.; Zhao, L.; Xue, Y. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. *J Surg Res* **2017**, 211, 266-278, doi:10.1016/j.jss.2016.11.067.
77. Wei, C.; Yang, C.; Wang, S.; Shi, D.; Zhang, C.; Lin, X.; Xiong, B. M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling. *Onco Targets Ther* **2019**, 12, 3051-3063, doi:10.2147/OTT.S198126.
78. Ji, L.; Qian, W.; Gui, L.; Ji, Z.; Yin, P.; Lin, G.N.; Wang, Y.; Ma, B.; Gao, W.Q. Blockade of β -Catenin-Induced CCL28 Suppresses Gastric Cancer Progression via Inhibition of Treg Cell Infiltration. *Cancer Res* **2020**, 80, 2004-2016, doi:10.1158/0008-5472.CAN-19-3074.
79. Xu, J.; Yu, Y.; He, X.; Niu, N.; Li, X.; Zhang, R.; Hu, J.; Ma, J.; Yu, X.; Sun, Y., et al. Tumor-associated macrophages induce invasion and poor prognosis in human gastric cancer in a cyclooxygenase-2/MMP9-dependent manner. *Am J Transl Res* **2019**, 11, 6040-6054.
80. Jorge, Y.C.; Mataruco, M.M.; Araújo, L.P.; Rossi, A.F.; de Oliveira, J.G.; Valsechi, M.C.; Caetano, A.; Miyazaki, K.; Fazzio, C.S.; Thomé, J.A., et al. Expression of annexin-A1 and galectin-1 anti-inflammatory proteins and mRNA in chronic gastritis and gastric cancer. *Mediators Inflamm* **2013**, 2013, 152860, doi:10.1155/2013/152860.
81. Lin, L.L.; Huang, H.C.; Juan, H.F. Revealing the molecular mechanism of gastric cancer marker annexin A4 in cancer cell proliferation using exon arrays. *PLoS One* **2012**, 7, e44615, doi:10.1371/journal.pone.0044615.
82. Jiang, J.; Zhao, W.; Tang, Q.; Wang, B.; Li, X.; Feng, Z. Over expression of amphiregulin promoted malignant progression in gastric cancer. *Pathol Res Pract* **2019**, 215, 152576, doi:10.1016/j.prp.2019.152576.
83. Wang, H.; Hu, L.; Zang, M.; Zhang, B.; Duan, Y.; Fan, Z.; Li, J.; Su, L.; Yan, M.; Zhu, Z., et al. REG4 promotes peritoneal metastasis of gastric cancer through GPR37. *Oncotarget* **2016**, 7, 27874-27888, doi:10.18632/oncotarget.8442.
84. Alpizar-Alpizar, W.; Laerum, O.D.; Illemann, M.; Ramírez, J.A.; Arias, A.; Malespín-Bendaña, W.; Ramírez, V.; Lund, L.R.; Borregaard, N.; Nielsen, B.S. Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with *Helicobacter pylori*. *Virchows Arch* **2009**, 455, 225-233, doi:10.1007/s00428-009-0825-8.
85. Wang, H.J.; He, X.J.; Ma, Y.Y.; Jiang, X.T.; Xia, Y.J.; Ye, Z.Y.; Zhao, Z.S.; Tao, H.Q. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test. *Anat Rec (Hoboken)* **2010**, 293, 1855-1863, doi:10.1002/ar.21230.
86. Liu, J.N.; Wang, H.B.; Zhou, C.C.; Hu, S.Y. CEACAM5 has different expression patterns in gastric non-neoplastic and neoplastic lesions and cytoplasmic staining is a marker for evaluation of tumor progression in gastric adenocarcinoma. *Pathol Res Pract* **2014**, 210, 686-693, doi:10.1016/j.prp.2014.06.024.

87. Zhou, J.; Fan, X.; Chen, N.; Zhou, F.; Dong, J.; Nie, Y.; Fan, D. Identification of CEACAM5 as a Biomarker for Prewarning and Prognosis in Gastric Cancer. *J Histochem Cytochem* **2015**, *63*, 922-930, doi:10.1369/0022155415609098.
88. Qiu, Y.S.; Liao, G.J.; Jiang, N.N. REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through PI3K/Akt signaling pathway. *Int J Mol Med* **2018**, *41*, 3167-3174, doi:10.3892/ijmm.2018.3520.
89. Choi, B.; Suh, Y.; Kim, W.H.; Christa, L.; Park, J.; Bae, C.D. Downregulation of regenerating islet-derived 3 alpha (REG3A) in primary human gastric adenocarcinomas. *Exp Mol Med* **2007**, *39*, 796-804, doi:10.1038/emmm.2007.86.
90. Li, L.; Zhu, Z.; Zhao, Y.; Zhang, Q.; Wu, X.; Miao, B.; Cao, J.; Fei, S. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics. *Sci Rep* **2019**, *9*, 7827, doi:10.1038/s41598-019-43924-x.
91. Thiel, A.; Mrena, J.; Ristimäki, A. Cyclooxygenase-2 and gastric cancer. *Cancer Metastasis Rev* **2011**, *30*, 387-395, doi:10.1007/s10555-011-9312-1.
92. Zhou, R.; Sun, J.; He, C.; Huang, C.; Yu, H. CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway. *Hum Cell* **2020**, *33*, 1120-1132, doi:10.1007/s13577-020-00375-1.
93. Prestin, K.; Olbert, M.; Hussner, J.; Isenegger, T.L.; Gliesche, D.G.; Böttcher, K.; Zimmermann, U.; Meyer Zu Schwabedissen, H.E. Modulation of expression of the nuclear receptor NR0B2 (small heterodimer partner 1) and its impact on proliferation of renal carcinoma cells. *Onco Targets Ther* **2016**, *9*, 4867-4878, doi:10.2147/OTT.S106926.
94. Xiang, Z.; Zhou, Z.J.; Xia, G.K.; Zhang, X.H.; Wei, Z.W.; Zhu, J.T.; Yu, J.; Chen, W.; He, Y.; Schwarz, R.E., et al. A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. *Oncogene* **2017**, *36*, 5122-5133, doi:10.1038/onc.2017.108.
95. Hu, C.; Lin, F.; Zhu, G.; Xue, X.; Ding, Y.; Zhao, Z.; Zhang, L.; Shen, X. Abnormal hypermethylation of promoter region downregulates chemokine CXCL14 expression in gastric cancer. *Int J Oncol* **2013**, *43*, 1487-1494, doi:10.3892/ijo.2013.2078.
96. Niu, W.; Guo, L.Y.; Zhang, J.Y.; Ji, T.; Mao, D.; Li, X.F.; Du, X.X. E2F1-induced upregulation of lncRNA HCG18 stimulates proliferation and migration in gastric cancer by binding to miR-197-3p. *Eur Rev Med Pharmacol Sci* **2020**, *24*, 9949-9956, doi:10.26355/eurev_202010_23207.
97. Chong, X.; Peng, R.; Sun, Y.; Zhang, L.; Zhang, Z. Identification of Key Genes in Gastric Cancer by Bioinformatics Analysis. *Biomed Res Int* **2020**, *2020*, 7658230, doi:10.1155/2020/7658230.
98. Zhang, Y.; Qin, L.; Ma, X.; Wang, Y.; Wu, Y.; Jiang, J. Coexpression of Matrix Metalloproteinase-7 and Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Biomarker in Gastric Cancer. *Dis Markers* **2020**, *2020*, 8831466, doi:10.1155/2020/8831466.
99. Zhao, Z.; Zhang, C.; Zhao, Q. S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer. *Scand J Gastroenterol* **2020**, *55*, 338-346, doi:10.1080/00365521.2020.1737883.
100. Wu, W.; Juan, W.C.; Liang, C.R.; Yeoh, K.G.; So, J.; Chung, M.C. S100A9, GIF and AAT as potential combinatorial biomarkers in gastric cancer diagnosis and prognosis. *Proteomics Clin Appl* **2012**, *6*, 152-162, doi:10.1002/prca.201100050.
101. Gordon-Weeks, A.; Lim, S.Y.; Yuzhalin, A.; Lucotti, S.; Vermeer, J.A.F.; Jones, K.; Chen, J.; Muschel, R.J. Tumour-Derived Laminin $\alpha 5$ (LAMA5) Promotes Colorectal Liver Metastasis Growth, Branching Angiogenesis and Notch Pathway Inhibition. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11050630.
102. Yu, Z.; Li, Z.; Wang, C.; Pan, T.; Chang, X.; Wang, X.; Zhou, Q.; Wu, X.; Li, J.; Zhang, J., et al. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M. *Gastric Cancer* **2019**, *22*, 955-966, doi:10.1007/s10120-019-00934-y.
103. Mukai, S.; Oue, N.; Oshima, T.; Imai, T.; Sekino, Y.; Honma, R.; Sakamoto, N.; Sentani, K.; Kuniyasu, H.; Egi, H., et al. Overexpression of PCDHB9 promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer. *J Pathol* **2017**, *243*, 100-110, doi:10.1002/path.4931.
104. Katoh, Y.; Katoh, M. Comparative integromics on Ephrin family. *Oncol Rep* **2006**, *15*, 1391-1395.

105. Guo, Y.; Yin, J.; Wang, Z.; Zha, L. Overexpression of platelet-derived growth factor-B increases the growth, invasion, and angiogenesis of gastric carcinoma cells through protein kinase B. *Neoplasma* **2013**, *60*, 605-612, doi:10.4149/neo_2013_078.
106. Ye, Y.W.; Zhou, Y.; Yuan, L.; Wang, C.M.; Du, C.Y.; Zhou, X.Y.; Zheng, B.Q.; Cao, X.; Sun, M.H.; Fu, H., et al. Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. *Cancer* **2011**, *117*, 5304-5313, doi:10.1002/cncr.26207.
107. Yan, S.; Wang, Y.; Chen, M.; Li, G.; Fan, J. Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer. *Int J Mol Sci* **2015**, *16*, 16144-16157, doi:10.3390/ijms160716144.
108. Li, C.; Zhang, J.; Wu, H.; Li, L.; Yang, C.; Song, S.; Peng, P.; Shao, M.; Zhang, M.; Zhao, J., et al. Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3 β activation. *Sci Rep* **2017**, *7*, 45275, doi:10.1038/srep45275.
109. Wan, S.; Xi, M.; Zhao, H.B.; Hua, W.; Liu, Y.L.; Zhou, Y.L.; Zhuo, Y.J.; Liu, Z.Z.; Cai, Z.D.; Wan, Y.P., et al. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer. *Pathol Res Pract* **2019**, *215*, 152464, doi:10.1016/j.prp.2019.152464.
110. Li, Z.; Wang, Y.; Dong, S.; Ge, C.; Xiao, Y.; Li, R.; Ma, X.; Xue, Y.; Zhang, Q.; Lv, J., et al. Association of CXCR1 and 2 expressions with gastric cancer metastasis in ex vivo and tumor cell invasion in vitro. *Cytokine* **2014**, *69*, 6-13, doi:10.1016/j.cyto.2014.05.004.
111. Wang, J.; Hu, W.; Wu, X.; Wang, K.; Yu, J.; Luo, B.; Luo, G.; Wang, W.; Wang, H.; Li, J., et al. CXCR1 promotes malignant behavior of gastric cancer cells in vitro and in vivo in AKT and ERK1/2 phosphorylation. *Int J Oncol* **2016**, *48*, 2184-2196, doi:10.3892/ijo.2016.3428.
112. Hou, X.L.; Ji, C.D.; Tang, J.; Wang, Y.X.; Xiang, D.F.; Li, H.Q.; Liu, W.W.; Wang, J.X.; Yan, H.Z.; Wang, Y., et al. FPR2 promotes invasion and metastasis of gastric cancer cells and predicts the prognosis of patients. *Sci Rep* **2017**, *7*, 3153, doi:10.1038/s41598-017-03368-7.
113. Li, M.L.; Zhang, J.C.; Li, S.G.; Wu, W.G.; Rao, L.H.; Dong, P.; Gu, J.; Lu, J.H.; Zhang, L.; Ding, Q.C., et al. Characteristic gene expression profiles in the progression from normal gastric epithelial cells to moderate gastric epithelial dysplasia and to gastric cancer. *Chin Med J (Engl)* **2012**, *125*, 1777-1783.
114. Agarwal, R.; Mori, Y.; Cheng, Y.; Jin, Z.; Olaru, A.V.; Hamilton, J.P.; David, S.; Selaru, F.M.; Yang, J.; Abraham, J.M., et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. *PLoS One* **2009**, *4*, e8002, doi:10.1371/journal.pone.0008002.
115. Jang, B.G.; Lee, B.L.; Kim, W.H. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer. *Virchows Arch* **2015**, *467*, 285-294, doi:10.1007/s00428-015-1793-9.
116. Choi, B.; Lee, H.J.; Min, J.; Choe, H.N.; Choi, Y.S.; Son, Y.G.; Ahn, H.S.; Suh, Y.S.; Goldenring, J.R.; Yang, H.K. Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer. *Cancer Biomark* **2017**, *19*, 231-239, doi:10.3233/CBM-160147.
117. Qiu, F.; Xiong, J.P.; Deng, J.; Xiang, X.J. TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. *Int J Clin Exp Pathol* **2015**, *8*, 5053-5061.
118. Kosaka, Y.; Inoue, H.; Ohmachi, T.; Yokoe, T.; Matsumoto, T.; Mimori, K.; Tanaka, F.; Watanabe, M.; Mori, M. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. *Ann Surg Oncol* **2007**, *14*, 2543-2549, doi:10.1245/s10434-007-9461-1.
119. Kanda, M.; Shimizu, D.; Tanaka, H.; Tanaka, C.; Kobayashi, D.; Hayashi, M.; Iwata, N.; Niwa, Y.; Yamada, S.; Fujii, T., et al. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. *Ann Surg* **2018**, *267*, 495-503, doi:10.1097/SLA.0000000000002096.
120. Xu, L.P.; Qiu, H.B.; Yuan, S.Q.; Chen, Y.M.; Zhou, Z.W.; Chen, Y.B. Downregulation of PSCA promotes gastric cancer proliferation and is related to poor prognosis. *J Cancer* **2020**, *11*, 2708-2715, doi:10.7150/jca.33575.
121. Dai, J.; Zhang, N.; Wang, J.; Chen, M.; Chen, J. Gastrophilin-2 is downregulated in gastric cancer and its restoration suppresses gastric tumorigenesis and cancer metastasis. *Tumour Biol* **2014**, *35*, 4199-4207, doi:10.1007/s13277-013-1550-0.

122. Yamashita, S.; Tsujino, Y.; Moriguchi, K.; Tatematsu, M.; Ushijima, T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. *Cancer Sci* **2006**, *97*, 64-71, doi:10.1111/j.1349-7006.2006.00136.x.
123. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. *CA Cancer J Clin* **2017**, *67*, 7-30, doi:10.3322/caac.21387.
124. Correa, P.; Houghton, J. Carcinogenesis of Helicobacter pylori. *Gastroenterology* **2007**, *133*, 659-672, doi:10.1053/j.gastro.2007.06.026.
125. Yu, Y. [Evaluation of traditional pathological classification at molecular classification era for gastric cancer]. *Zhonghua Wei Chang Wai Ke Za Zhi* **2014**, *17*, 18-20.
126. Sarriugarte Lasarte, A.; García Alberdi, E.; Martínez Indart, L.; Gutierrez Grijalba, O.; Albarez Abad, I.; Guerra Lerma, M.; Calle Baraja, M.; Colina Alonso, A. "From Lauren's diffuse gastric cancer to WHO's poorly cohesive carcinoma." Clinicopathological and prognostic characteristics. *Rev Esp Enferm Dig* **2020**, doi:10.17235/reed.2020.7184/2020.
127. Verkman, A.S.; Hara-Chikuma, M.; Papadopoulos, M.C. Aquaporins--new players in cancer biology. *J Mol Med (Berl)* **2008**, *86*, 523-529, doi:10.1007/s00109-008-0303-9.
128. Chen, Q.; Zhu, L.; Zheng, B.; Wang, J.; Song, X.; Zheng, W.; Wang, L.; Yang, D. Effect of AQP9 Expression in Androgen-Independent Prostate Cancer Cell PC3. *Int J Mol Sci* **2016**, *17*, doi:10.3390/ijms17050738.
129. Warth, A.; Mittelbronn, M.; Hülper, P.; Erdlenbruch, B.; Wolburg, H. Expression of the water channel protein aquaporin-9 in malignant brain tumors. *Appl Immunohistochem Mol Morphol* **2007**, *15*, 193-198, doi:10.1097/01.pai.0000213110.05108.e9.
130. Zhang, W.G.; Li, C.F.; Liu, M.; Chen, X.F.; Shuai, K.; Kong, X.; Lv, L.; Mei, Z.C. Aquaporin 9 is down-regulated in hepatocellular carcinoma and its over-expression suppresses hepatoma cell invasion through inhibiting epithelial-to-mesenchymal transition. *Cancer Lett* **2016**, *378*, 111-119, doi:10.1016/j.canlet.2016.05.021.
131. Huang, D.; Feng, X.; Liu, Y.; Deng, Y.; Chen, H.; Chen, D.; Fang, L.; Cai, Y.; Liu, H.; Wang, L., et al. AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer. *Cell Death Dis* **2017**, *8*, e2894, doi:10.1038/cddis.2017.282.
132. De Santis, S.; Serino, G.; Fiorentino, M.R.; Galleggiante, V.; Gena, P.; Verna, G.; Liso, M.; Massaro, M.; Lan, J.; Troisi, J., et al. Corrigendum: Aquaporin-9 Contributes to the Maturation Process and Inflammatory Cytokine Secretion of Murine Dendritic Cells. *Front Immunol* **2019**, *10*, 216, doi:10.3389/fimmu.2019.00216.
133. Moniaga, C.S.; Watanabe, S.; Honda, T.; Nielsen, S.; Hara-Chikuma, M. Aquaporin-9-expressing neutrophils are required for the establishment of contact hypersensitivity. *Sci Rep* **2015**, *5*, 15319, doi:10.1038/srep15319.
134. Zhu, L.; Ma, N.; Wang, B.; Wang, L.; Zhou, C.; Yan, Y.; He, J.; Ren, Y. Significant prognostic values of aquaporin mRNA expression in breast cancer. *Cancer Manag Res* **2019**, *11*, 1503-1515, doi:10.2147/CMAR.S193396.
135. Liu, X.; Xu, Q.; Li, Z.; Xiong, B. Integrated analysis identifies AQP9 correlates with immune infiltration and acts as a prognosticator in multiple cancers. *Sci Rep* **2020**, *10*, 20795, doi:10.1038/s41598-020-77657-z.
136. Thapa, S.; Chetry, M.; Huang, K.; Peng, Y.; Wang, J.; Zhou, Y.; Shen, Y.; Xue, Y.; Ji, K. Significance of aquaporins' expression in the prognosis of gastric cancer. *Biosci Rep* **2018**, *38*, doi:10.1042/BSR20171687.
137. Komohara, Y.; Fujiwara, Y.; Ohnishi, K.; Shiraishi, D.; Takeya, M. Contribution of Macrophage Polarization to Metabolic Diseases. *J Atheroscler Thromb* **2016**, *23*, 10-17, doi:10.5551/jat.32359.
138. Zotti, T.; Polvere, I.; Voccola, S.; Vito, P.; Stilo, R. CARD14/CARMA2 Signaling and its Role in Inflammatory Skin Disorders. *Front Immunol* **2018**, *9*, 2167, doi:10.3389/fimmu.2018.02167.
139. Harden, J.L.; Lewis, S.M.; Pierson, K.C.; Suárez-Fariñas, M.; Lentini, T.; Ortenzio, F.S.; Zaba, L.C.; Goldbach-Mansky, R.; Bowcock, A.M.; Lowes, M.A. CARD14 expression in dermal endothelial cells in psoriasis. *PLoS One* **2014**, *9*, e111255, doi:10.1371/journal.pone.0111255.

140. Jordan, C.T.; Cao, L.; Roberson, E.D.; Pierson, K.C.; Yang, C.F.; Joyce, C.E.; Ryan, C.; Duan, S.; Helms, C.A.; Liu, Y., et al. PSORS2 is due to mutations in CARD14. *Am J Hum Genet* **2012**, *90*, 784-795, doi:10.1016/j.ajhg.2012.03.012.
141. Scudiero, I.; Zotti, T.; Ferravante, A.; Vessichelli, M.; Vito, P.; Stilo, R. Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF- κ B activation and endoplasmic reticulum stress-induced cell death. *J Cell Physiol* **2011**, *226*, 3121-3131, doi:10.1002/jcp.22667.
142. Lim, J.Y.; Kim, S.W.; Kim, B.; Park, S.J. Knockdown of CARD14 Inhibits Cell Proliferation and Migration in Breast Cancer Cells. *Anticancer Res* **2020**, *40*, 1953-1962, doi:10.21873/anticancer.14150.
143. Kasashima, H.; Yashiro, M.; Nakamae, H.; Kitayama, K.; Masuda, G.; Kinoshita, H.; Fukuoka, T.; Hasegawa, T.; Nakane, T.; Hino, M., et al. CXCL1-Chemokine (C-X-C Motif) Receptor 2 Signaling Stimulates the Recruitment of Bone Marrow-Derived Mesenchymal Cells into Diffuse-Type Gastric Cancer Stroma. *Am J Pathol* **2016**, *186*, 3028-3039, doi:10.1016/j.ajpath.2016.07.024.
144. Acharyya, S.; Oskarsson, T.; Vanharanta, S.; Malladi, S.; Kim, J.; Morris, P.G.; Manova-Todorova, K.; Leversha, M.; Hogg, N.; Seshan, V.E., et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell* **2012**, *150*, 165-178, doi:10.1016/j.cell.2012.04.042.
145. Steele, C.W.; Karim, S.A.; Leach, J.D.G.; Bailey, P.; Upstill-Goddard, R.; Rishi, L.; Foth, M.; Bryson, S.; McDaid, K.; Wilson, Z., et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. *Cancer Cell* **2016**, *29*, 832-845, doi:10.1016/j.ccell.2016.04.014.
146. Highfill, S.L.; Cui, Y.; Giles, A.J.; Smith, J.P.; Zhang, H.; Morse, E.; Kaplan, R.N.; Mackall, C.L. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. *Sci Transl Med* **2014**, *6*, 237ra267, doi:10.1126/scitranslmed.3007974.
147. Izumi, K.; Fang, L.Y.; Mizokami, A.; Namiki, M.; Li, L.; Lin, W.J.; Chang, C. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. *EMBO Mol Med* **2013**, *5*, 1383-1401, doi:10.1002/emmm.201202367.
148. Kasashima, H.; Yashiro, M.; Nakamae, H.; Masuda, G.; Kinoshita, H.; Morisaki, T.; Fukuoka, T.; Hasegawa, T.; Nakane, T.; Hino, M., et al. Clinicopathologic significance of the CXCL1-CXCR2 axis in the tumor microenvironment of gastric carcinoma. *PLoS One* **2017**, *12*, e0178635, doi:10.1371/journal.pone.0178635.
149. Wang, J.; Hu, W.; Wang, K.; Yu, J.; Luo, B.; Luo, G.; Wang, W.; Wang, H.; Li, J.; Wen, J. Repertaxin, an inhibitor of the chemokine receptors CXCR1 and CXCR2, inhibits malignant behavior of human gastric cancer MKN45 cells in vitro and in vivo and enhances efficacy of 5-fluorouracil. *Int J Oncol* **2016**, *48*, 1341-1352, doi:10.3892/ijo.2016.3371.

Figure Legends

Figure 1. RNA sequencing of Diffuse and Intestinal Gastric Cancer. (A) Heterogeneity characterization of gastric samples showed by principal component analysis (PCA) plot. (B) Scatter plots of transcripts differentially expressed between diffuse gastric cancer and healthy mucosa or intestinal gastric cancer and healthy mucosa. (Fold Change <-2 or $>+2$, p value <0.05).

Figure 2. Transcriptome analysis. Venn Diagram analysis of differentially expressed genes in Diffuse (subset A) and Intestinal (subset B) gastric cancer samples compared with healthy mucosa, showing the overlapping region (identified AB subset) containing transcripts differentially expressed in both gastric cancer histotypes (Fold Change <-2 or $>+2$, p value <0.05).

Figure 3. Per pathways analysis of Subset A. Analysis of 407 transcripts differentially modulated only in Diffuse Gastric Cancer vs Healthy Gastric Mucosa: identification of several pathways that can be grouped in three principal clusters: Proliferation, differentiation and metabolism, Inflammation and Signalling.

Figure 4. Per pathways analysis of Subset B. Analysis of 772 transcripts differentially modulated only in Intestinal Gastric Cancer vs Healthy Gastric Mucosa: identification of several pathways that can be grouped in three principal clusters: Proliferation, differentiation and metabolism, Inflammation and Signalling.

Figure 5. Functional enrichment analysis of Histotype-specific genes. Functional enrichment results of diffuse gastric-specific genes and intestinal-specific genes performed separately using DAVID tools.

Figure 6. Identification of Histotype-specific genes. List of Differential Expressed Genes (DEGs) obtained using stringent criteria (threshold of FDR ≤ 0.1 and fold-change ≥ 3 applied) in (A) diffuse gastric cancer and (B) intestinal gastric cancer compared with healthy mucosa. (C) List of DEGs selected by using the stringent criteria between Intestinal gastric cancer and Diffuse gastric cancer samples.

Figure 7. Clinical results. (A) 4-year overall survival (4Y-OS) of the study population. (B) Kaplan-Meier survival curve showing the 4Y-OS of intestinal and diffuse group. ($p < 0.05$).

Figure 8. Univariate analysis. Analysis of 4Y-OS performed as described in material and method section according sex (panels A and B) or N/L ratio status (panels C and D) in diffuse and intestinal groups. ($p < 0.05$).

Figure 9. Impact of gene expression in overall survival. (A) Patients were dichotomized into 2 groups according to the median value of expression each gene. (B) Impact of AQP9 gene expression on patient survival in the intestinal group. Impact of (C) CXCR2 and (D) CARD14 on patient survival in the diffuse group. ($p < 0.05$).

A

PCA plot

B

Figure 1

Venn Diagram

Figure 2

Analysis of Subset A: 407 transcripts differentially modulated only in Diffuse GC vs Healthy Gastric Mucosa

Inflammation

IL-18 signaling pathway
Spinal Cord Injury
IL1 and megakaryocytes in obesity
Type II interferon signaling (IFNG)
Interleukin-6 family signaling
Chemokine signaling pathway
Development and heterogeneity of the ILC family
TNF alpha Signaling Pathway
TNF related weak inducer of apoptosis Signaling Pathway
Prostaglandin Synthesis and Regulation
Toll-like Receptor Signaling Pathway

Signaling

VEGFA-VEGFR2 Signaling Pathway
Nuclear Receptors Meta-Pathway
Histone Modifications
Insulin Signaling
Ras Signaling
PI3K-Akt Signaling Pathway
NRF2 pathway
Brain-Derived Neurotrophic Factor (BDNF) signaling pathway
ErbB Signaling Pathway
Statin Pathway
G Protein Signaling Pathways
Vitamin D Receptor Pathway

Proliferation, differentiation and metabolism

Mesodermal Commitment Pathway
Plasma lipoprotein assembly, remodeling, and clearance
Adipogenesis
Cholesterol metabolism
DNA Replication
G1 to S cell cycle control
Genotoxicity pathway
Trans-sulfuration pathway
Oxidative Stress
Fatty Acid Biosynthesis
Apoptosis-related network due to altered Notch3
Ectoderm Differentiation
Activation of gene expression by SREBF (SREBP)
Angiogenesis overview
Metapathway biotransformation Phase I and II

Figure 3

Analysis of Subset B: 772 transcripts differentially modulated only in Intestinal GC vs Healthy Gastric Mucosa

Inflammation

- IL-18 signaling pathway
- Chemokine signaling pathway
- Spinal Cord Injury
- Prostaglandin Synthesis and Regulation
- B Cell Receptor Signaling Pathway
- T-Cell antigen Receptor (TCR) Signaling Pathway
- IL1 and megakaryocytes in obesity
- TGF-beta Receptor Signaling
- Interferon type I signaling pathways
- Inflammatory Response Pathway

Signaling

- Focal Adhesion-PI3K-Akt-mTOR-signaling pathway
- Nuclear Receptors Meta-Pathway
- PI3K-Akt Signaling Pathway
- MAPK Signaling Pathway
- VEGFA-VEGFR2 Signaling Pathway
- GPCRs, Class A Rhodopsin-like
- NRF2 pathway
- Vitamin D Receptor Pathway
- Ras Signaling
- Regulatory circuits of the STAT3 signaling pathway
- PPAR signaling pathway
- Glucocorticoid Receptor Pathway
- Gastrin Signaling Pathway
- Wnt Signaling
- Nuclear Receptors
- EGF/EGFR Signaling Pathway
- JAK/STAT
- BDNF signaling pathway
- ErbB Signaling Pathway
- Insulin Signaling
- G Protein Signaling Pathways

Proliferation, differentiation and metabolism

- Focal Adhesion
- Class A/1 (Rhodopsin-like receptors)
- Mesodermal Commitment Pathway
- Endoderm Differentiation
- Regulation of Actin Cytoskeleton
- Genotoxicity pathway
- Epithelial to mesenchymal transition
- Senescence and Autophagy in Cancer
- Cholesterol metabolism
- ESC Pluripotency Pathways
- Ectoderm Differentiation
- Adipogenesis
- Glycolysis and Gluconeogenesis
- Pyrimidine metabolism
- Apoptosis-related network due to altered Notch3
- Apoptosis Modulation and Signaling
- DNA Damage Response
- Tryptophan metabolism
- Oxidation by Cytochrome P450
- Glycolysis Pathway D (2)
- Oxidative Stress
- Differentiation Pathway
- TGF-B Signaling for Epithelial-Mesenchymal Transition
- Oncostatin M Signaling Pathway
- Fatty Acid Omega Oxidation
- Integrin-mediated Cell Adhesion
- Folate Metabolism
- Eicosanoid metabolism via Lipo Oxygenases (LOX)
- Eicosanoid metabolism via Cyclo Oxygenases (COX)

Figure 4

Functional enrichment results of Histotype-specific genes.

Figure 5

A

List of most DEG in Diffuse GC vs Healthy Mucosa

ID	Diffuse GC Avg (log2)	Healthy Gastric Mucosa (log2)	Fold Change	P-val	FDR P-val	
CEACAM5	8,16	5,5	<div></div>	6,34	0,0034	0,0942
LIPG	3,96	1,96	<div></div>	4,01	0,0016	0,0659
PRSS3	6,73	4,81	<div></div>	3,8	0,0029	0,0861
APOC1	5,5	3,6	<div></div>	3,75	0,003	0,0876
FAM83B	5,22	3,53	<div></div>	3,22	0,0004	0,0353
LINC00152	2,33	0,66	<div></div>	3,19	4,85E-05	0,0187
MMP9	4,3	2,67	<div></div>	3,1	0,0041	0,1

B

List of most DEG in Intestinal GC vs Healthy Mucosa

ID	Intestinal GC Avg (log2)	Healthy Gastric Mucosa (log2)	Fold Change	P-val	FDR P-val
OLFM4	5,63	2,27	<div><div></div></div> 10,26	0,0033	0,0589
EFNA2	2,72	0,05	<div><div></div></div> 6,37	0,0003	0,014
TRIM29	3,53	1,11	<div><div></div></div> 5,37	0,0012	0,0329
CARD14	3,25	0,93	<div><div></div></div> 5	4,71E-05	0,0052
AQP9	3,32	1,01	<div><div></div></div> 4,96	0,0004	0,0167
PTGS2	5,64	3,34	<div><div></div></div> 4,95	0,0006	0,0213
SYT8	4,38	2,14	<div><div></div></div> 4,74	0,003	0,0557
FPR2	2,61	0,47	<div><div></div></div> 4,41	6,86E-06	0,0018
OLR1	2,51	0,38	<div><div></div></div> 4,37	1,82E-05	0,0031
TRIP13	4,94	2,86	<div><div></div></div> 4,25	6,08E-05	0,006
CXCR2	2,05	0	<div><div></div></div> 4,15	0,0022	0,0471
SLC2A1	6,47	4,45	<div><div></div></div> 4,06	5,78E-06	0,0017
SERPINE1	6,05	4,08	<div><div></div></div> 3,94	0,0007	0,0235
S100A9	5,6	3,64	<div><div></div></div> 3,91	0,0056	0,0796
CXCR1	1,98	0,06	<div><div></div></div> 3,78	0,0004	0,017
GREM1	1,95	3,79	<div><div></div></div> -3,58	0,0063	0,085
TTR	1,35	3,77	<div><div></div></div> -5,37	0,0005	0,0184
SFRP2	0,76	3,44	<div><div></div></div> -6,42	0,0052	0,0767
BMPRI1B	0,46	3,15	<div><div></div></div> -6,44	0,0079	0,0966
ALDH3A1	4,92	7,7	<div><div></div></div> -6,88	0,0022	0,0461
HHIP	0,92	3,74	<div><div></div></div> -7,08	0,0037	0,0627
KLK11	1,65	4,5	<div><div></div></div> -7,24	0,0009	0,0272
CCL19	1,69	4,55	<div><div></div></div> -7,26	0,0055	0,0788
GKN2	5,15	8,51	<div><div></div></div> -10,28	0,0051	0,0757
PSCA	5,95	9,33	<div><div></div></div> -10,47	0,006	0,0827
GHRL	1,48	5,73	<div><div></div></div> -18,93	0,0002	0,0109

List of most DEG in Intestinal GC vs Diffuse GC

C

ID	Intestinal GC Avg (log2)	Diffuse GC Avg (log2)	Fold Change	P-val	
FPR2	2,61	0,53	<div></div>	4,24	0,0008
CARD14	3,25	1,38	<div></div>	3,64	0,0325
CXCR2	2,05	0,46	<div></div>	3,01	0,0187
EFNA2	2,72	1,19	<div></div>	2,88	0,0122
CXCR1	1,98	0,56	<div></div>	2,68	0,0065
AQP9	3,32	1,98	<div></div>	2,54	0,0214
TRIP13	4,94	3,84	<div></div>	2,16	0,0289
KLK11	1,65	3,83	<div></div>	-4,54	0,0497
GHRL	1,48	4,4	<div></div>	-7,58	0,02

Figure 6

A

B

Figure 7

Figure 8

A

B

C

D

Figure 9